{"version":1,"pages":[{"id":"JsKd452Nu8XTrHz68zaF","title":"Home","pathname":"/myhealingcommunity-docs","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based guide to anti-cancer compounds, molecules, support resources, and community discussion directories in integrative oncology","breadcrumbs":[{"label":"Home","icon":"house"}]},{"id":"zS5Iyd263iQiVFk66Xk4","title":"Senolytic Pulse Protocol","pathname":"/myhealingcommunity-docs/senolytic-pulse-protocol","siteSpaceId":"sitesp_Rf4YD","description":"Conservative, patient-facing framework for intermittent natural senolytic-style pulses built around fisetin and quercetin.","breadcrumbs":[{"label":"Home","icon":"house"}]},{"id":"DIBeBMCS6fVKeMnSRVrw","title":"Overview","pathname":"/myhealingcommunity-docs/natural-medicines/overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of the natural medicines library, including compound hubs and practical guidance on liposomal delivery","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"Dk81LHYCagxj1nbLQNkA","title":"Direct links to our natural medicines in oncology deep dives and FB group's conversation threads","pathname":"/myhealingcommunity-docs/natural-medicines/direct-links-to-our-natural-medicines-in-oncology-deep-dives-and-fb-groups-conversation-threads","siteSpaceId":"sitesp_Rf4YD","description":"Overview of the natural medicines library, including deep dives, liposomal delivery guidance, and the A–Z group discussion thread index","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"QMzLJHpxezAkvLVFsYEy","title":"Berberine in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology","siteSpaceId":"sitesp_Rf4YD","description":"Deep-dive guide to berberine in oncology, including mechanisms, evidence summary, pharmacology context, and safety cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"dV4vtIl51sugAr8cOGF5","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of berberine in oncology, including strengths, limits, clinical positioning, and key treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"cM3DXH6sTQvLGFW4VXUz","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of berberine and why they matter in oncology research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"PZ0FmTNR9RpJQmA2jXol","title":"Redox Dual Action","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/redox-dual-action","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent oxidative and antioxidant activity of berberine in cancer biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"etvjTmWcGQtH3jmifpfD","title":"Glucose, Glutamine & the Warburg Effect","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/glucose-glutamine-and-the-warburg-effect","siteSpaceId":"sitesp_Rf4YD","description":"How berberine disrupts glucose uptake, glycolysis, and glutamine dependence in cancer cells","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"nkJD1hxiD3ZWqFE5Vb9u","title":"Ferroptosis Findings","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/ferroptosis-findings","siteSpaceId":"sitesp_Rf4YD","description":"Emerging evidence that berberine can promote ferroptosis in selected cancer models","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"wEoHjofnqUKRPf24Ay7n","title":"NRF2 Impact","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/anticancer-mechanisms/nrf2-impact","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent berberine effects on the Nrf2 pathway and why that matters in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"WFJIMGrJyK0gKcDSr5O4","title":"Berberine Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to berberine in oncology research, including colorectal, breast, lung, gastric, gynaecological, and brain-tumour evidence","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"l9wFSbjwHjrimslGVfVD","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of berberine in breast cancer, including TNBC, ER-positive, and HER2-positive resistance-reversal research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Berberine Evidence by Cancer Type"}]},{"id":"Ss9WUYYSX1AC1ZO79AsM","title":"Lung Cancer (NSCLC)","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/lung-cancer-nsclc","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of berberine in non-small-cell lung cancer, including p53-independent growth arrest, cancer-stem-cell effects, and ferroptosis-linked findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Berberine Evidence by Cancer Type"}]},{"id":"bPJhsbCq5baMAz4z7RqL","title":"Gastric Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/gastric-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of berberine in gastric cancer, including JAK2/STAT3 inhibition, glycolysis effects, and low-glucose synergy","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Berberine Evidence by Cancer Type"}]},{"id":"CbYoZU2OoxeRcADyA5Ia","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of berberine in colorectal cancer, including adenoma-prevention data, microbiome relevance, and cetuximab-sensitisation research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Berberine Evidence by Cancer Type"}]},{"id":"BORkDzhDLiucIsS1VLys","title":"Gynaecological Cancers","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/gynaecological-cancers","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of berberine in ovarian, cervical, and endometrial cancers, including metastasis, HPV, and PI3K/Akt-related findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Berberine Evidence by Cancer Type"}]},{"id":"vCb5q7mSQuWM1JNGWn4n","title":"Glioblastoma & Brain Tumours","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-evidence-by-cancer-type/glioblastoma-and-brain-tumours","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of berberine in glioblastoma and brain-tumour research, including autophagy, glycolysis pressure, and delivery challenges","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"},{"label":"Berberine Evidence by Cancer Type"}]},{"id":"Bu8V7FilCiG6CrmSsqPD","title":"Immune Effects","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How berberine may remodel the tumour microenvironment, reduce PD-L1 signalling, and support anti-tumour immunity","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"fC6CDLZuIQSLfdWBuqQg","title":"Antimicrobial / Antifungal Activity","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/antimicrobial-antifungal-activity","siteSpaceId":"sitesp_Rf4YD","description":"Berberine's antimicrobial and antifungal activity, including H. pylori, Fusobacterium nucleatum, Candida, and microbiome relevance in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"argBrZno1zOIDDsMrrw1","title":"Pharmacokinetics & Metabolism","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/pharmacokinetics-and-metabolism","siteSpaceId":"sitesp_Rf4YD","description":"Berberine bioavailability limits, gut-microbiome conversion, tissue distribution, and formulation considerations in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"p3tkCsxIuP4bkw96e4Lt","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Berberine safety profile, CYP and P-glycoprotein interaction risks, and monitoring considerations in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"nyC0YVjHvN1Dda1Nhrj6","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"Berberine dosing ranges, meal timing, fasting context, and formulation-adjusted use in oncology discussions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"JpJMOWal5BJwOaAJeC6v","title":"Berberine & Metformin","pathname":"/myhealingcommunity-docs/natural-medicines/berberine-in-oncology/berberine-and-metformin","siteSpaceId":"sitesp_Rf4YD","description":"Why berberine and metformin are usually better used as a continuous metabolic backbone rather than alternated in cycles","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Berberine in Oncology"}]},{"id":"3DwR9EIp6j3GLmKHjFjv","title":"Boswellia in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"AHJkiIOeCPFQUf2oiQp7","title":"Boswellia in Oncology Overview","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-in-oncology-overview","siteSpaceId":"sitesp_Rf4YD","description":"What Boswellia is, how it relates to frankincense, and why AKBA matters in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"BGSyOi5J0pG5ut95LvWl","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of Boswellia in oncology, including AKBA strengths, clinical positioning, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"k47w3fsMzXsxE1G2y4cZ","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of Boswellia and AKBA in oncology research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"AOn9RUWhQlTeRgJyhaaJ","title":"Boswellia Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to Boswellia in oncology, including glioblastoma, breast, colorectal, pancreatic, prostate, lung, ovarian, and related research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"rBuSCeKUrUN3VaU6fNYn","title":"Glioblastoma & Brain Tumours","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/glioblastoma-and-brain-tumours","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Boswellia in glioblastoma and brain tumours, including cerebral oedema and radiosensitisation relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"fsUBC8pJroVXpRA6zSTr","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Boswellia in breast cancer, including Phase Ia human data, EGFR signalling, and apoptosis research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"qgHfCuAj2ZKmDPNECQC4","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Boswellia in colorectal cancer, including orthotopic model data, miRNA effects, and invasion suppression","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"ECI9yt97Pgee7AQsbTHQ","title":"Pancreatic Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Boswellia in pancreatic cancer, including orthotopic tumour suppression and COX-2-related mechanisms","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"HJYMK0a3gFplbVOBVjAX","title":"Prostate Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Boswellia in prostate cancer, including docetaxel-resistance reversal and Akt / STAT3 suppression","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"tS5Bry8Q7cnrsR6fekIb","title":"Non-Small Cell Lung Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/non-small-cell-lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Boswellia in NSCLC, including cisplatin sensitisation and radioresistance reversal","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"Dl5emlBXtaFRPuabfpCS","title":"Ovarian Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/ovarian-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Boswellia in ovarian cancer, including taxane-resistance and multidrug-resistance findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"cOlZAF00XpQyydB1dF1J","title":"Other Cancer Types","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/boswellia-evidence-by-cancer-type/other-cancer-types","siteSpaceId":"sitesp_Rf4YD","description":"Additional Boswellia oncology evidence across liver, gastric, haematologic, melanoma, and other cancer models","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"},{"label":"Boswellia Evidence by Cancer Type"}]},{"id":"Cic2oScJOl9n4eBgI0y4","title":"Redox Dual Action","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/redox-dual-action","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent oxidative and anti-inflammatory activity of Boswellia and AKBA","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"1SCK8LT6PbwjYzX6ELbU","title":"NRF2 Impact","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/nrf2-impact","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent Nrf2 interpretation for Boswellia and AKBA in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"9L0gTh2DMlVc90wQrdBE","title":"Ferroptosis Findings","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/ferroptosis-findings","siteSpaceId":"sitesp_Rf4YD","description":"Emerging ferroptosis relevance of Boswellia and AKBA in resistant tumour biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"iPArBntDPgYWo7xLkjFF","title":"Immune Effects","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How Boswellia/AKBA modulates inflammatory mediators and anti-tumour immune function","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"Ts3YTzcBtwwmiS9nI3Zd","title":"Pharmacokinetics & Metabolism","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/pharmacokinetics-and-metabolism","siteSpaceId":"sitesp_Rf4YD","description":"How Boswellia and AKBA are absorbed, metabolised, and limited by bioavailability","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"IFxqjkts0jt69VD08Mp2","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Safety profile, CYP interactions, anticoagulant cautions, and monitoring considerations for Boswellia in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"KVJO4L389yT0lwJWkq0K","title":"Synergistic Combinations","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/synergistic-combinations","siteSpaceId":"sitesp_Rf4YD","description":"How Boswellia and AKBA may combine with chemotherapy, radiotherapy, and other natural compounds","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"CX1KnUx42wFSoqH5itkw","title":"Hydroxychloroquine + Boswellia","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/hydroxychloroquine-+-boswellia","siteSpaceId":"sitesp_Rf4YD","icon":"flag-swallowtail","description":"Special report on hydroxychloroquine and Boswellia / AKBA as a dual autophagy-blocking strategy, including prostate-cancer evidence and cardiac cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"CGG1qfj1AlmaBlwk2jUf","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"Boswellia and AKBA dosing logic, clinical trial ranges, food timing, and formulation considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"f1vUJJb8lv5rtotHBCd0","title":"Sourcing Quality Boswellia","pathname":"/myhealingcommunity-docs/natural-medicines/boswellia-in-oncology/sourcing-quality-boswellia","siteSpaceId":"sitesp_Rf4YD","description":"How to judge Boswellia extract quality, AKBA standardisation, and formulation relevance for oncology-oriented use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Boswellia in Oncology"}]},{"id":"cVbaofn5RsGCpcLbq1H6","title":"Curcumin in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"04QiHU1SRIRdptb8yBfE","title":"Curcumin in Oncology Overview","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-in-oncology-overview","siteSpaceId":"sitesp_Rf4YD","description":"What curcumin is, why it is studied in oncology, and where the evidence is strongest across prevention and adjunctive care","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"1CnE5T2LKn5hO2xu6WSY","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of curcumin in oncology, including clinical positioning, advantages, limitations, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"uSz3iGR3fVgRWEYknmL4","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of curcumin","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"6CcinSpY6gpG9lfdpVuu","title":"Redox Dual Action","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/anticancer-mechanisms/redox-dual-action","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent curcumin redox activity explaining selective toxicity toward cancer cells","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"yUa2DfwZQ0sVw9l11ChZ","title":"NRF2 Impact","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/anticancer-mechanisms/nrf2-impact","siteSpaceId":"sitesp_Rf4YD","description":"Curcumin's activation of the Nrf2 pathway and why it matters clinically","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"ILVk8RikeH4mimgjz5EQ","title":"Ferroptosis Findings","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/anticancer-mechanisms/ferroptosis-findings","siteSpaceId":"sitesp_Rf4YD","description":"Emerging evidence that curcumin can induce ferroptosis in resistant cancer cells","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"Y0LTcW6D272hUy5wAGmS","title":"Curcumin Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to curcumin in oncology, including colorectal, breast, pancreatic, lung, prostate, gastric, head and neck, and blood cancer research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"nqevX5fblFmlu4FB9G1s","title":"Blood Cancers","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/blood-cancers","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in blood cancers, including myeloma, CLL, ALL, and lymphoma research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"xzrVl16PwrgAJScZxLgw","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in colorectal cancer, including chemoprevention, FOLFOX synergy, stem-cell targeting, and resistance data","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"FDTSsge36LNZvDhgqo9E","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in breast cancer, including subtype-specific data, taxane synergy, radiotherapy support, and resistance research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"ncylHJiFlFvrGn7BhBV9","title":"Pancreatic Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in pancreatic cancer, including Phase II clinical data and gemcitabine-sensitising research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"3L9VJrzqMke0zra0dMSz","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in lung cancer and other lung cancers: mechanisms, preclinical findings, and clinical direction","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"Vz1CxJ7RYBmhfvBAZtUY","title":"Prostate Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in prostate cancer: human trial data, pathway-specific mechanisms, and honest assessment of the evidence","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"9WwYLsWkdpgXfZThmmu0","title":"Head & Neck Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/head-and-neck-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in head and neck cancer, including mucositis support and anti-metastatic findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"ahf0o74Gj8KOiFyWVHXJ","title":"Gastric Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/gastric-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of curcumin in gastric cancer, including H. pylori relevance and inflammation-linked mechanisms","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"},{"label":"Curcumin Evidence by Cancer Type"}]},{"id":"w4TIKWdc1izG2VeyXCjx","title":"Immune Effects","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How curcumin may support anti-tumour immune function","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"mMnpXS2VETpeuFLSlVKV","title":"Antimicrobial / Antifungal Activity","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/antimicrobial-antifungal-activity","siteSpaceId":"sitesp_Rf4YD","description":"Curcumin's antimicrobial properties and their possible relevance to cancer biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"wCEQe9yBWr9kg168m0i6","title":"Pharmacokinetics & Metabolism","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/pharmacokinetics-and-metabolism","siteSpaceId":"sitesp_Rf4YD","description":"Curcumin bioavailability, drug interactions, and delivery considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"gvLlE8XByOzUJbsrQ1TW","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"Curcumin timing, dosing logic, and clinically relevant formulation considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"sg1e7YrJbtYRPcsof66m","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Curcumin safety profile, contraindications, and monitoring considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"LmWfCU3lcgWQkav73lj0","title":"Synergistic Combinations","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/synergistic-combinations","siteSpaceId":"sitesp_Rf4YD","description":"Curcumin combinations with chemotherapy and natural compounds","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"webRV7Q7rcqhc08wcISv","title":"Sourcing Quality Curcumin","pathname":"/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/sourcing-quality-curcumin","siteSpaceId":"sitesp_Rf4YD","description":"How to judge curcumin supplement quality, bioavailability, actual curcuminoid strength, and real-world value for oncology-oriented use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Curcumin in Oncology"}]},{"id":"UIG6MbV0qqIiMHTUg73K","title":"Deuterium-Depleted Water (DDW)","pathname":"/myhealingcommunity-docs/natural-medicines/deuterium-depleted-water-ddw","siteSpaceId":"sitesp_Rf4YD","description":"DDW section landing page covering what it is, why it matters in oncology, protocol questions, evidence by cancer type, and where to jump next","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"mdeLVj366Eonb82Z6k3t","title":"DDW Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/deuterium-depleted-water-ddw/ddw-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to DDW in oncology research, including pancreatic, colorectal, breast, lung, nasopharyngeal, prostate, and mixed-clinical settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Deuterium-Depleted Water (DDW)"}]},{"id":"USC7rO1ggNqSRK4B4cRZ","title":"DDW and Pancreatic Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/deuterium-depleted-water-ddw/ddw-evidence-by-cancer-type/ddw-and-pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of DDW in pancreatic cancer, including the 2021 adjunctive chemotherapy survival study and its limits","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Deuterium-Depleted Water (DDW)"},{"label":"DDW Evidence by Cancer Type"}]},{"id":"4EJ0JH8vq3VTDVVewJTY","title":"DDW Protocol Variation and Lower Limits","pathname":"/myhealingcommunity-docs/natural-medicines/deuterium-depleted-water-ddw/ddw-protocol-variation-and-lower-limits","siteSpaceId":"sitesp_Rf4YD","description":"Why DDW experts differ on how low to go, including the Somlyai step-down model, the ~80 ppm caution, and the glycocalyx theory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Deuterium-Depleted Water (DDW)"}]},{"id":"M0CZ8p3ZRzQFY1avWLho","title":"DDW Sourcing and Brand Options","pathname":"/myhealingcommunity-docs/natural-medicines/deuterium-depleted-water-ddw/ddw-sourcing-and-brand-options","siteSpaceId":"sitesp_Rf4YD","description":"Practical guide to DDW product formats, ppm options, mixing logic, and how to think about brands without overstating differences","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Deuterium-Depleted Water (DDW)"}]},{"id":"N9Exnrm3IFMGkQeYZLJJ","title":"EGCG in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"Ff5WbXRVziP3zVEPy9G0","title":"EGCG in Oncology Overview","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-in-oncology-overview","siteSpaceId":"sitesp_Rf4YD","description":"What EGCG is, how it relates to green tea, and why it is studied in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"atNYLumj3ItJW9xvlhxh","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of EGCG in oncology, including clinical positioning, strengths, limitations, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"K3YkBGrjXeG0u5YLWh09","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of EGCG and the green tea catechin evidence base","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"lAl0G6CUo3s0vGg0zSoW","title":"EGCG Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to EGCG in oncology, including breast, pancreatic, colorectal, lung, prostate, blood, and oral cancer research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"zfA0gB0p4Pco12cUC2Pq","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of EGCG in breast cancer, including subtype-specific data, treatment synergy, and recurrence-related research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"Ix48PJyrLbnXmC8gLgbJ","title":"Pancreatic Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of EGCG in pancreatic cancer, including gemcitabine synergy and tumour-growth inhibition research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"7tBIRYpX57rSUUdnyJQU","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of EGCG in colorectal cancer, including chemoprevention, local GI relevance, and 5-FU-related research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"nuspOhqJ6ZQv5vsaEHgW","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of EGCG in lung cancer, including EGFR relevance, NSCLC research, and ferroptosis-related findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"Sm9Cz1JtT7E5b4WjP26Y","title":"Prostate Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of EGCG in prostate cancer, including prevention trials, biomarker effects, and androgen-related relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"RLSVYUb7FzzYopWMSEQX","title":"Blood Cancers","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/blood-cancers","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of EGCG in blood cancers, including CLL, leukaemia, lymphoma, and bortezomib-related cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"0SNiPp0PcCoHrciDQF5Y","title":"Oral / Head & Neck Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/oral-head-and-neck-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of EGCG in oral and head and neck cancers, including topical relevance and invasion-related findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"79imbXJdRCs2jJCKP5J6","title":"Other Cancer Types","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/egcg-evidence-by-cancer-type/other-cancer-types","siteSpaceId":"sitesp_Rf4YD","description":"Additional EGCG oncology evidence across ovarian, gastric, liver, and other cancer models","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"},{"label":"EGCG Evidence by Cancer Type"}]},{"id":"uPacD2FVaejUwMjK6Uin","title":"Immune Effects","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How EGCG and the main green tea catechin may support anti-tumour immune function","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"JSAZAuKxqc74Rf6eqBKl","title":"Pharmacokinetics & Metabolism","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/pharmacokinetics-and-metabolism","siteSpaceId":"sitesp_Rf4YD","description":"How EGCG is absorbed, metabolised, and limited by poor oral bioavailability in oncology use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"cDsUt5NRin8HZ8zKK1M9","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"EGCG dosing logic for prevention, adjunctive use, bioavailability, and treatment timing","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"yw111kP9tzvfoZ22WSkU","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Safety profile, liver risk, drug interactions, and bortezomib caution for EGCG in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"vn7rD6iobk1Zp6b5R5py","title":"Sourcing Quality EGCG","pathname":"/myhealingcommunity-docs/natural-medicines/egcg-in-oncology/sourcing-quality-egcg","siteSpaceId":"sitesp_Rf4YD","description":"How to judge EGCG supplement quality, green tea extract strength, caffeine issues, and bioavailability considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"EGCG in Oncology"}]},{"id":"wq6jULnlqEMXkPT2xjbt","title":"Liposomal Encapsulation of Anti-cancer Compounds","pathname":"/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds","siteSpaceId":"sitesp_Rf4YD","description":"Why empty liposomes matter, how to use them, and safety-focused guides to liposomal melatonin and ivermectin","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"XOGadvyILtzMO7XwNfrZ","title":"Why Empty Liposomes Matter","pathname":"/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/why-empty-liposomes-matter","siteSpaceId":"sitesp_Rf4YD","description":"Why empty phosphatidylcholine liposomes may have biological activity of their own, and why that matters here","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Liposomal Encapsulation of Anti-cancer Compounds"}]},{"id":"peAyo46UlAjHWTUxTOx3","title":"Safety, Timing, and Stacking Cautions","pathname":"/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/safety-timing-and-stacking-cautions","siteSpaceId":"sitesp_Rf4YD","description":"Key safety considerations when combining liposomal delivery with lipophilic drugs or supplements","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Liposomal Encapsulation of Anti-cancer Compounds"}]},{"id":"aKaRPciqY3MpqHejl4QU","title":"How to Use Liposence® Empty Liposomes","pathname":"/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/how-to-use-liposence-r-empty-liposomes","siteSpaceId":"sitesp_Rf4YD","description":"Practical notes on choosing ingredients, mixing, storage, and everyday use of Liposence empty liposomes","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Liposomal Encapsulation of Anti-cancer Compounds"}]},{"id":"PHFk8bZzpsL7aelRoUKd","title":"DIY Liposomal Melatonin","pathname":"/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/diy-liposomal-melatonin","siteSpaceId":"sitesp_Rf4YD","description":"Recipe notes, costing logic, storage, and comparison points for DIY liposomal melatonin using empty liposomes","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Liposomal Encapsulation of Anti-cancer Compounds"}]},{"id":"fgxEKz43q2YLtNuYE48T","title":"Liposomal Ivermectin","pathname":"/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/liposomal-ivermectin","siteSpaceId":"sitesp_Rf4YD","description":"Experimental evidence, formulation notes, recipe math, and safety cautions for liposomal ivermectin","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Liposomal Encapsulation of Anti-cancer Compounds"}]},{"id":"rfmTKGGcEAMmB6efb1S4","title":"Nebulising Liposomal Formulations","pathname":"/myhealingcommunity-docs/natural-medicines/liposomal-encapsulation-of-anti-cancer-compounds/nebulising-liposomal-formulations","siteSpaceId":"sitesp_Rf4YD","description":"Advanced note on nebulised liposomal delivery, with pulmonary uptake, retention, and safety references","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Liposomal Encapsulation of Anti-cancer Compounds"}]},{"id":"z4ksmiNTFsF1nmvFByZe","title":"Polydatin in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"pvQXkcWyGWIoXZC87SVv","title":"Polydatin in Oncology Overview","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-in-oncology-overview","siteSpaceId":"sitesp_Rf4YD","description":"What polydatin is and where the evidence is strongest in oncology research.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"gMOBYznRp2bVrkV4YY4L","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of polydatin in oncology, including advantages, limitations, clinical positioning, and key treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"iWifCqN7xkhg1bGiDS8r","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of Polydatin","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"4WRCnx3EcvATZAqnGYdT","title":"G6PD Inhibition","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/g6pd-inhibition","siteSpaceId":"sitesp_Rf4YD","icon":"keyboard-brightness","description":"Polydatin G6PD inhibition, including cancer types showing particular G6PD-dependent vulnerability","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"qyIbeYADJOg0qk3M76l8","title":"Redox Dual Action","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/redox-dual-action","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent polydatin redox activity explaining selective toxicity toward cancer cells while sparing normal tissues","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"j96HT7sKY5GX8jn8xx4T","title":"NRF2 Impact","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/nrf2-impact","siteSpaceId":"sitesp_Rf4YD","description":"Polydatin effects on the Nrf2 pathway and why that context matters in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"WmAIZxzSNy1jtuMEdlZS","title":"Ferroptosis Findings","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/ferroptosis-findings","siteSpaceId":"sitesp_Rf4YD","description":"Emerging ferroptosis relevance of polydatin in cancer biology and treatment resistance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"OSsHnR3mkpTKX6iy3goI","title":"CYP1B1 Rescue Mechanism","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/cyp1b1-rescue-mechanism","siteSpaceId":"sitesp_Rf4YD","icon":"keyboard-brightness","description":"Includes Discussion of Polydatin's Unique Mechanisms for Anti-Cancer, Antimicrobial and Anti-fungal Activity","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"cfZi1TPBXKzL7nCg3ihv","title":"GLUT uptake advantage","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/anticancer-mechanisms/glut-uptake-advantage","siteSpaceId":"sitesp_Rf4YD","description":"Polydatin carries a glucose moiety, structurally recognised by GLUT transporters to a degree that resveratrol is not.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"fLkWU6Mh2kG5qlogn9gE","title":"Polydatin Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to polydatin in oncology research findings, including colorectal, breast, lung, liver, oral, blood, and bone cancer research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"SOVitUsY54WO8U8k9b2U","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of polydatin in colorectal cancer, including radiosensitisation, oxaliplatin synergy, and mechanism data","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"1eIlCKjiSD4LZNw5Me0P","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of polydatin across breast cancers, including signalling effects, cautions, and","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"lF1m9UmvT7mWg0TQNmhA","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of polydatin in lung cancer, including apoptosis, cell-cycle arrest, and cisplatin-synergy findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"mgLjG9cAvevoAUZLPEz8","title":"Liver Cancer (HCC)","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/liver-cancer-hcc","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of polydatin in liver cancer, including tumour selectivity, apoptosis, and chemotherapy-sensitising effects","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"JQsbR0qvl3p4rjtAnLi7","title":"Oral Cancer (OSCC)","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/oral-cancer-oscc","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of polydatin in oral cancer, including G6PD inhibition, anti-metastatic effects, and orthotopic model data","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"cizS3cjK30aMN2bsmKFQ","title":"Blood Cancers","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/blood-cancers","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of polydatin in blood cancers, including AML and ALL findings on apoptosis, autophagy, and growth inhibition","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"NNfm0kPX5xIfrvWxUCMt","title":"Osteosarcoma","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/osteosarcoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of polydatin in osteosarcoma, including radiosensitisation, apoptosis, and doxorubicin-resistance findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"9DACtVbLNwJWvm2aEYU8","title":"Other Cancer Types","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/other-cancer-types","siteSpaceId":"sitesp_Rf4YD","description":"Additional polydatin oncology evidence across nasopharyngeal, cervical, ovarian, and other cancer models - work in progress","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"ZuBUJTwWPyhS8E2T6wvP","title":"HER2+ Cancers","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-evidence-by-cancer-type/her2+-cancers","siteSpaceId":"sitesp_Rf4YD","icon":"flag-swallowtail","description":"HER2-positive breast-cancer caution for polydatin and the current Δ16HER2 / resveratrol concern","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"},{"label":"Polydatin Evidence by Cancer Type"}]},{"id":"g5pmr2SvVkYUx7VZb02U","title":"Immune Effects","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"Polydatin blocks G6PD, and G6PD blockade may help trigger anti-tumour immune effects","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"XhkV0HT4Xu2xrMK6N3Ky","title":"Antimicrobial / Antifungal Activity","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/antimicrobial-antifungal-activity","siteSpaceId":"sitesp_Rf4YD","description":"Polydatin antimicrobial and antifungal activity, including tumour-mycobiome relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"Ww0dzV6d3D89oBEMSNG7","title":"Pharmacokinetics & Metabolism","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/pharmacokinetics-and-metabolism","siteSpaceId":"sitesp_Rf4YD","description":"Polydatin bioavailability, drug interactions, and delivery considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"zk9H6cH0W5SAoVBIofEe","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Safety profile, interaction risks, and practical considerations for polydatin in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"7UyAT372YZHYrq1wGW7L","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"Polydatin dosing logic, timing, and formulation considerations in oncology use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"icaKCk9KRl7XuaRG17uj","title":"Polydatin / Resveratrol Comparison","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/polydatin-resveratrol-comparison","siteSpaceId":"sitesp_Rf4YD","description":"Comparison of polydatin and resveratrol, including mechanism, uptake, and bioavailability differences","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"flGEAkSeI6kia7ticHFo","title":"Sourcing Quality Polydatin","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/sourcing-quality-polydatin","siteSpaceId":"sitesp_Rf4YD","description":"How to judge polydatin supplement quality, bioavailability, strength, and real-world value for oncology-oriented use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"kLMdEkffiva2NfZSDcmt","title":"PDF Pack","pathname":"/myhealingcommunity-docs/natural-medicines/polydatin-in-oncology/pdf-pack","siteSpaceId":"sitesp_Rf4YD","description":"Export-friendly ordered pack for Polydatin pages","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Polydatin in Oncology"}]},{"id":"VnJjrH1WZTg4DZOKQEyK","title":"Shikonin in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology","siteSpaceId":"sitesp_Rf4YD","description":"Deep-dive guide to shikonin in oncology, including mechanisms, immune effects, evidence by cancer type, pharmacokinetics, and safety cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"19zT9Sp0ecF4rXoeRcrH","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of shikonin in oncology, including strengths, limitations, clinical positioning, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"sVSzVL4YCXoSc3B2VZXp","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anticancer mechanisms of shikonin and why they matter in oncology research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"9LJCQMVu2BlgKK1vqP3p","title":"Immune Effects","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How shikonin may affect immunogenic cell death, tumour-associated macrophages, and the wider tumour microenvironment","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"1vEwXfYlL9TDACQ7xBlT","title":"Shikonin Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to shikonin in oncology research across breast, bladder, oesophageal, ovarian, cervical, lung, and thyroid cancer settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"eAQFwNaBj9Pq3Kq0lT2i","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of shikonin in breast cancer, including ER-pathway disruption, PKM2 relevance, necroptosis, and tamoxifen synergy","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"},{"label":"Shikonin Evidence by Cancer Type"}]},{"id":"cbmpMXrtIvACQUVX8Phq","title":"Bladder Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/bladder-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of shikonin in bladder cancer, including PKM2-driven resistance reversal, necroptosis, and cisplatin sensitisation","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"},{"label":"Shikonin Evidence by Cancer Type"}]},{"id":"eijcNlRn3h9dJQJcO6aC","title":"Oesophageal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/oesophageal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of shikonin in oesophageal squamous cell carcinoma, including PKM2 and STAT3-linked glycolysis suppression","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"},{"label":"Shikonin Evidence by Cancer Type"}]},{"id":"kxKkXYzX2bnw0Stae87e","title":"Ovarian Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/ovarian-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of shikonin in ovarian cancer, including exosome biology, β-catenin signalling, and macrophage effects","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"},{"label":"Shikonin Evidence by Cancer Type"}]},{"id":"0jP07IjvGg050UQgDDZq","title":"Cervical Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/cervical-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of shikonin in cervical cancer, including EMT suppression and PI3K/AKT/mTOR-related findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"},{"label":"Shikonin Evidence by Cancer Type"}]},{"id":"jYiZ2p21121pWPTFabzJ","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of shikonin in lung cancer, including PI3K/AKT/mTOR signalling and gefitinib sensitisation relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"},{"label":"Shikonin Evidence by Cancer Type"}]},{"id":"oRFquuOVO70CJ31VLbMt","title":"Thyroid Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonin-evidence-by-cancer-type/thyroid-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of shikonin in anaplastic thyroid cancer, including the current ferroptosis signal and its limits","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"},{"label":"Shikonin Evidence by Cancer Type"}]},{"id":"0kKCEUj1znbgq1OujHMG","title":"Pharmacokinetics & Metabolism","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/pharmacokinetics-and-metabolism","siteSpaceId":"sitesp_Rf4YD","description":"Shikonin bioavailability limits, metabolism, formulation challenges, and why delivery remains the main translational barrier","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"oGs6MPPCfWQkNuYpSCXv","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Shikonin safety profile, liver biology, CYP450 interaction evidence, endocrine-treatment questions, and key interaction limits in oncology use.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"RUXatgNPYmqIf6mvFREE","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"What the research used, what the one human clinical signal shows, and why no established dose exists for oncology use.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"3rbIv5oOOByoXSt3wxwg","title":"Sourcing Quality Shikonin","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/sourcing-quality-shikonin","siteSpaceId":"sitesp_Rf4YD","description":"How to judge shikonin product quality, why standardisation matters, and what current market limits still look like","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"mtubmxpWVHypYBNHCSyP","title":"Synergistic Combinations","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/synergistic-combinations","siteSpaceId":"sitesp_Rf4YD","description":"Preclinical shikonin combination data across endocrine therapy, chemotherapy, and targeted therapy contexts","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"QStYN7b9e9rlFRwIDRYU","title":"Sensitisation to Conventional Therapies","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/sensitisation-to-conventional-therapies","siteSpaceId":"sitesp_Rf4YD","description":"How shikonin may re-open treatment sensitivity through PKM2 inhibition, ER-pathway disruption, and non-apoptotic cell death","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"BQffz1dXy15r1lnOEadS","title":"PKM2 & the Warburg Effect","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/pkm2-and-the-warburg-effect","siteSpaceId":"sitesp_Rf4YD","description":"Why PKM2 is the central shikonin mechanism, how it links to the Warburg effect, and why that matters across cancer types","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"atxrpf83PwGMxPkFX9sU","title":"Shikonon's Estrogen Receptor Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/shikonin-in-oncology/shikonons-estrogen-receptor-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Detailed breakdown of Shikonin's ERα, GPER, steroid-sulfatase, and downstream signalling effects in hormone-driven cancer models","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Shikonin in Oncology"}]},{"id":"tFtSRT6IGmRQ1n3c2vEv","title":"Silymarin / Milk Thistle in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"gvjOp3NuyYacQ0d7GM8m","title":"Silymarin / Milk Thistle in Oncology Overview","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-in-oncology-overview","siteSpaceId":"sitesp_Rf4YD","description":"What silymarin is, how it relates to milk thistle, and why it matters in oncology for liver protection, treatment support, and anticancer research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"fLUXxwKKhZRg2bqUDyYp","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of silymarin and milk thistle in oncology, including liver protection, clinical positioning, advantages, and limitations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"2OBJPpBIof1vMFuKgiM6","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of silymarin and milk thistle","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"qkuDruf5jOOYZjmn4yHN","title":"Redox Dual Action","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/anticancer-mechanisms/redox-dual-action","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent redox activity of silymarin and milk thistle in cancer biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"xcjHx6AVI5SKWJxcXYE6","title":"Silymarin / Milk Thistle Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to silymarin and milk thistle in oncology, including breast, prostate, colorectal, liver, skin, lung, pancreatic, bladder, and ovarian cancer research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"F72L705IPofWEFqw1fIb","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and milk thistle in breast cancer, including chemotherapy support, signalling effects, and radiotherapy relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"HyYRnkxGnOkfl5RPjAXF","title":"Prostate Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and milk thistle in prostate cancer, including chemoprevention and androgen-pathway research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"RysGFSDTerp2vLbJ83Lt","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and milk thistle in colorectal cancer, including chemotherapy synergy and PD-L1 findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"0CjRHMhVl4XxnSb3vICX","title":"Liver Cancer (HCC)","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/liver-cancer-hcc","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and milk thistle in liver cancer, including fasting-mimetic findings and hepatoprotective relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"oZI5olkxFedUlGhTo3Eq","title":"Melanoma and Other Skin Cancers","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/melanoma-and-other-skin-cancers","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and milk thistle in skin cancer, including UV-related chemoprevention and radiodermatitis relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"nX5dyqvv7aUkvxkBsO94","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and milk thistle in lung cancer, including apoptosis, cell-cycle arrest, and anti-angiogenic findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"N1mOksBelUY3XOUetGVo","title":"Pancreatic Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and milk thistle in pancreatic cancer, including proliferative signalling, apoptosis, metastasis, metabolism, and cachexia","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"09QYCh9nKUWVj1GHdTG7","title":"Bladder Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/bladder-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of silymarin and bladder cancer, including effects on proliferative signalling, apoptosis, invasion and metastasis, epithelial–mesenchymal transition, and stress‑response path.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"UYRziEtad7i8fZVT8JO2","title":"Ovarian Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/ovarian-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence‑based overview of silymarin and ovarian cancer, including proliferative signalling, apoptosis and cell‑cycle arrest, EMT and metastasis, platinum sensitisation, and related gyno contexts.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"HOMS4y4uSSIQvhg3UVSo","title":"Cervical Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/silymarin-milk-thistle-evidence-by-cancer-type/cervical-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence‑based overview of silymarin and cervical cancer, including effects on signalling, apoptosis, G2/M cell‑cycle arrest, stress‑response MAPK pathways, IC potential.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"},{"label":"Silymarin / Milk Thistle Evidence by Cancer Type"}]},{"id":"4d4SDl3VSeq7Q2MUx6Lz","title":"Chemotherapy & Radiation Synergy","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/chemotherapy-and-radiation-synergy","siteSpaceId":"sitesp_Rf4YD","description":"How silymarin and milk thistle may enhance treatment while protecting healthy tissue","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"Bqyhy8qZuZk8QXZ3fth4","title":"Immune Modulation & PD-L1","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/immune-modulation-and-pd-l1","siteSpaceId":"sitesp_Rf4YD","description":"Emerging immune-oncology relevance of silymarin and milk thistle","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"joRlGvHAl914mJrOKed7","title":"Nrf2 & NF-κB Pathway Deep Dive","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/nrf2-and-nf-kb-pathway-deep-dive","siteSpaceId":"sitesp_Rf4YD","description":"Context-dependent pathway interpretation for silymarin and milk thistle in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"gERPQWT6RGd4N4ghHMan","title":"Pharmacokinetics, Bioavailability & Dosing","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/pharmacokinetics-bioavailability-and-dosing","siteSpaceId":"sitesp_Rf4YD","description":"How silymarin and milk thistle are absorbed, processed, and dosed in research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"XZlVdNO3ts7WLts97gl9","title":"Safety, Interactions & Considerations","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/safety-interactions-and-considerations","siteSpaceId":"sitesp_Rf4YD","description":"Safety profile, interaction risks, and clinical considerations for silymarin and milk thistle","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"o27R9prRmPQzRKVbsNaT","title":"Sourcing & Product Quality","pathname":"/myhealingcommunity-docs/natural-medicines/silymarin-milk-thistle-in-oncology/sourcing-and-product-quality","siteSpaceId":"sitesp_Rf4YD","description":"How to judge milk thistle and silymarin supplement quality, standardisation, strength, and product value for oncology-oriented use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Silymarin / Milk Thistle in Oncology"}]},{"id":"b8jAoz76BR2TRoyjbuAx","title":"Urolithin A in Oncology","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology","siteSpaceId":"sitesp_Rf4YD","description":"Deep-dive guide to Urolithin A in oncology, including mechanisms, immune effects, evidence by cancer type, pharmacokinetics, and safety cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"ABBKTpwCzY8nH1zcBM8J","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of Urolithin A in oncology, including strengths, limitations, clinical positioning, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"x6jYrpRi7LqHuwd323gK","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anticancer mechanisms of Urolithin A and why they matter in oncology research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"Bc3Nl09L0EVA47hQtlDT","title":"Immune Effects","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How Urolithin A may affect NK cells, CD8-positive T cells, macrophage behaviour, and immunotherapy-relevant biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"9lSnIsRui6p2oKituFCD","title":"Synergistic Combinations","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/synergistic-combinations","siteSpaceId":"sitesp_Rf4YD","description":"How Urolithin A may combine with immunotherapy and selected standard therapies in oncology research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"J7bd2wA8jOzXV4q3CIXd","title":"Urolithin A Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to Urolithin A in oncology research across GI, hormonal, urothelial, liver, lung, brain, prostate, and bone-cancer settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"AS5SlOB5fvTZdXWXPaWn","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in colorectal cancer, including Wnt signalling, AKT1-related immune effects, apoptosis, and chemotherapy-sensitisation research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"X0vD1oCifNHCv40DeEdD","title":"Pancreatic Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in pancreatic cancer, including PI3K/AKT/mTOR suppression, stromal remodelling, gemcitabine context, and anti-PD-1 sensitisation","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"AAfSPWfVtkvWKCl19bFY","title":"Prostate Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in prostate cancer, including androgen-receptor signalling, oxidative DNA damage, NK-cell activation, and the active URO-PRO trial","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"YUuKG55zDuHF3NvhwNrD","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in breast cancer, including ER-positive signalling, triple-negative macrophage effects, ABCG2 relevance, and key subtype limits","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"DMlOKOXP86ma2vdbQLZE","title":"Endometrial Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/endometrial-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in endometrial cancer, including ERα and ERβ modulation, G2/M arrest, and the current lack of in vivo or clinical data","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"LKaPUg9KG0tQeglYiZEp","title":"Glioblastoma","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/glioblastoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in glioblastoma, including blood-brain-barrier penetration, Sirt1-FOXO1 signalling, AKT and EGFR suppression, and tumour-microenvironment effects","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"Wiyt22i57omFPdvcMry7","title":"Liver Cancer (HCC)","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/liver-cancer-hcc","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in hepatocellular carcinoma, including β-catenin signalling, HBV-related mechanisms, Nrf2-related hepatoprotection, and gut-liver-axis relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"tTcVtxP27I85djnuQFxn","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in lung cancer, including EMT inhibition, PI3K/AKT/mTOR suppression, autophagy, and in vivo xenograft findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"dMDVEu9po1rQ0tAvbYxu","title":"Osteosarcoma","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/osteosarcoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in osteosarcoma, including anti-metastatic findings, AKT1 and EGFR relevance, and MMP2 and MMP9 suppression","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"fY90z4GQpt5uM0FOkw4e","title":"Bladder Cancer","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/urolithin-a-evidence-by-cancer-type/bladder-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of Urolithin A in bladder cancer, including UMUC3 sensitivity, G2/M arrest, apoptosis, and urinary-exposure relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"},{"label":"Urolithin A Evidence by Cancer Type"}]},{"id":"gJY7cHVa7NGq2FFLc9sC","title":"Pharmacokinetics & Metabolism","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/pharmacokinetics-and-metabolism","siteSpaceId":"sitesp_Rf4YD","description":"Urolithin A bioavailability, microbiome-conversion limits, tissue-distribution questions, and supplementation implications","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"htaI9KmmoIwkxn8zCVdF","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Human safety data, drug-interaction uncertainty, endocrine cautions, and immunotherapy-related considerations for Urolithin A","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"ynPr8xFf4KmH2oGdjhxX","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"Human dose ranges, practical timing notes, and current dosing limits for Urolithin A in oncology discussions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"wHTzvkLG2Q5QeGA3yHdK","title":"Sourcing Quality Urolithin A","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sourcing-quality-urolithin-a","siteSpaceId":"sitesp_Rf4YD","description":"How to judge Urolithin A supplement quality, compare real-world products, and avoid underdosed or misleading formulas","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"VOCRr4oKM8VCvY7xRNGx","title":"Antimicrobial, Antiviral & Terrain Support","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/antimicrobial-antiviral-and-terrain-support","siteSpaceId":"sitesp_Rf4YD","description":"Terrain-focused guide to Urolithin A across antibacterial, antiviral, antiparasitic, antifungal, gut-barrier, and microbiome-support evidence relevant to cancer care","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"0VDxwJnZsSf6arJPTEnD","title":"Sensitisation to Conventional Therapies","pathname":"/myhealingcommunity-docs/natural-medicines/urolithin-a-in-oncology/sensitisation-to-conventional-therapies","siteSpaceId":"sitesp_Rf4YD","description":"How Urolithin A may sensitise cancer cells to chemotherapy, immunotherapy, and radiation across current preclinical and early human evidence","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Urolithin A in Oncology"}]},{"id":"zSIGJOrjYimLhEVsMtA6","title":"Usnic Acid / Usnea","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of usnic acid from Usnea, including anticancer mechanisms, antifungal crossover, dosing context, and safety cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"}]},{"id":"Dz4xC4gDxl1OYs8tiyki","title":"Usnic Acid / Usnea in Oncology Overview","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/usnic-acid-usnea-in-oncology-overview","siteSpaceId":"sitesp_Rf4YD","description":"What usnic acid is, why it is studied in oncology, and where the evidence is strongest","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"56qOfQpingD8uPfahCTZ","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of usnic acid in oncology, including strengths, limitations, clinical positioning, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"fIp1IJPWbPCz84GVow7O","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anticancer mechanisms of usnic acid and why they matter in oncology research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"3PrsyDv1Aj4ukWROc3jw","title":"Biofilm Activity","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/biofilm-activity","siteSpaceId":"sitesp_Rf4YD","description":"What usnic acid appears to do against fungal-bacterial biofilms and where its limits begin","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"KzvQPlAXx3uN8r0laCqr","title":"Usnic Acid Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/usnic-acid-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to usnic acid research findings across major tumour models","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"gEdiLYb76kfSv375hGQg","title":"Antifungal / Antimicrobial Activity","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/antifungal-antimicrobial-activity","siteSpaceId":"sitesp_Rf4YD","description":"Usnic acid's antifungal crossover relevance and why it matters in this documentation set","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"6ApPqBmxhMa95hdz5bvd","title":"Synergy with Standard Therapies","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/synergy-with-standard-therapies","siteSpaceId":"sitesp_Rf4YD","description":"Why usnic acid has drawn interest as a possible sensitising partner with selected cancer drugs","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"SaphdXrthctKkw4Rno98","title":"Safety & Hepatotoxicity","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/safety-and-hepatotoxicity","siteSpaceId":"sitesp_Rf4YD","description":"Liver-risk context, selectivity, and why dose and formulation matter so much for usnic acid","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"kmCkcq2108O0nmrMgPsE","title":"Dosing & Timing","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/dosing-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"Practical tincture dosing context, cycling, standardisation limits, and timing considerations for usnic acid","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"EKs8ebxzTPSpgUvUqSeZ","title":"Sourcing Quality Usnea / Usnic Acid","pathname":"/myhealingcommunity-docs/natural-medicines/usnic-acid-usnea/sourcing-quality-usnea-usnic-acid","siteSpaceId":"sitesp_Rf4YD","description":"Product-quality considerations, standardisation problems, and example sourcing notes for usnea tinctures","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Natural medicines"},{"label":"Usnic Acid / Usnea"}]},{"id":"ITy6YZRafzQPqdYLjt3b","title":"Integrative Practitioner Directories Overview","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-practitioner-directories-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of integrative oncology practitioner directories and related clinic-offering pages","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"}]},{"id":"pYpJrgcOcMIhCo3zWM7a","title":"Integrative Oncology Services and Practitioner Directories","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories","siteSpaceId":"sitesp_Rf4YD","description":"Community-curated practitioner directories and related service pages for integrative oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"}]},{"id":"ZvS7k5ewUZKNwzAEejnd","title":"Practitioner List: Europe & UK","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk","siteSpaceId":"sitesp_Rf4YD","description":"Community-curated list of integrative oncology clinics and related practitioners across Europe and the UK","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"}]},{"id":"8XG157hvSZjXAjMG5Hg9","title":"Belgium","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/belgium","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Belgium from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"7JTxItxASoTqVyhZtmf9","title":"Denmark","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/denmark","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Denmark from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"914E6nWeYpNhAdvhDlCP","title":"Germany","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/germany","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Germany from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"1PWgAaJZ6uMCmdS33kbi","title":"Romania","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/romania","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Romania from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"cP6wsv1vu1Ae7ynC59Ih","title":"Ireland","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/ireland","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Ireland from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"bjSBBgLRXeONMwZE02wW","title":"Scotland","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/scotland","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Scotland from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"BmtO7ZEwsZCiiRrPra0G","title":"Netherlands","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/netherlands","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in the Netherlands from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"ECFwtuoIui04fB1BX2Uk","title":"Spain","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/spain","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Spain from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"YB0GJYC4UH8oTn7dlJJU","title":"Switzerland","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/switzerland","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Switzerland from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"zw63Y5UQE24Nb161dJh4","title":"UK","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/uk","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in the UK from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"Kz5dkHOiz3HThHqY1POz","title":"Turkey","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/turkey","siteSpaceId":"sitesp_Rf4YD","description":"Integrative oncology and practitioner entries in Turkey from the Europe and UK directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"Z9VGwwnSj9qCkcxPsTkY","title":"Additional Testing Providers","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-europe-and-uk/additional-testing-providers","siteSpaceId":"sitesp_Rf4YD","description":"Additional Europe-linked testing-provider entries from the practitioner directory","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"},{"label":"Practitioner List: Europe & UK"}]},{"id":"MzsK9FSGjQ5B6QtK71OZ","title":"Practitioner List: New Zealand","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/integrative-oncology-services-and-practitioner-directories/practitioner-list-new-zealand","siteSpaceId":"sitesp_Rf4YD","description":"Community-curated list of integrative practitioners and clinics in New Zealand","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"},{"label":"Integrative Oncology Services and Practitioner Directories"}]},{"id":"0bcrCh4nLPVLeO1vf5iK","title":"Conventional Drugs; Facebook Group Support and Discussion Threads A–Z","pathname":"/myhealingcommunity-docs/cancer-therapies-+-clinic-offerings/conventional-drugs-facebook-group-support-and-discussion-threads-a-z","siteSpaceId":"sitesp_Rf4YD","description":"A–Z index of Healing Cancer Study Support Group discussion threads for conventional oncology drugs and related support topics","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Therapies + Clinic Offerings"}]},{"id":"TAxT9IhFV1fotgP8NLK8","title":"Off-Label Drugs for Cancer Overview","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/off-label-drugs-for-cancer-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of off-label drugs for cancer, including repurposed-drug topic hubs and practical treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"}]},{"id":"Rw8C9uU0329qLRJ6iqZy","title":"FLCC Approach to Repurposed Drugs in Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/flcc-approach-to-repurposed-drugs-in-cancer","siteSpaceId":"sitesp_Rf4YD","description":"How the two FLCC cancer-care guides fit together, and a quick dosing index for navigation","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"}]},{"id":"uIoTwSvoVpqOfT3a3ofW","title":"Mebendazole in Oncology","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology","siteSpaceId":"sitesp_Rf4YD","description":"Deep-dive guide to mebendazole in oncology, including mechanisms, cancer-type evidence, dosing, safety, and sourcing","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"}]},{"id":"4QJMGi9BT67iItPgeg2b","title":"Mebendazole Overview","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-overview","siteSpaceId":"sitesp_Rf4YD","description":"What mebendazole is, why it is studied in oncology, and where the evidence is strongest","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"0pIDWxR7uJzvq5N907oC","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of mebendazole in oncology, including strengths, limitations, clinical positioning, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"Uc7JXF9L0EadPDyCFLc6","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of mebendazole and why it is a serious repurposing candidate","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"QzHo29PWwZHzCuzkYo91","title":"Mebendazole Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to mebendazole in oncology, including ovarian, breast, colorectal, brain, lung, and other cancer research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"4z3KtkddR8Cj6vD4FU7q","title":"Ovarian Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type/ovarian-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of mebendazole in ovarian cancer, including metastasis, tubulin, and Akt / NF-κB findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"},{"label":"Mebendazole Evidence by Cancer Type"}]},{"id":"ZJ6fGFEG98gISpvWNdyu","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of mebendazole in breast cancer, including HIF suppression, stem-like-cell effects, and hypoxia-related biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"},{"label":"Mebendazole Evidence by Cancer Type"}]},{"id":"45ETlEFJOW6Py8BvoR2o","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of mebendazole in colorectal cancer, including anti-VEGF signals and tolerated clinical dosing","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"},{"label":"Mebendazole Evidence by Cancer Type"}]},{"id":"oJA1dO0WRs2ISvYdybp0","title":"Brain Tumours","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type/brain-tumours","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of mebendazole in brain tumours, including medulloblastoma and CNS repurposing relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"},{"label":"Mebendazole Evidence by Cancer Type"}]},{"id":"hC3JGnAjshZWuCnTbc9o","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of mebendazole in lung cancer, including ERK relevance and broader signalling interest","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"},{"label":"Mebendazole Evidence by Cancer Type"}]},{"id":"j9unXD5N7ua8h5isLc6j","title":"Other Cancer Types","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/mebendazole-evidence-by-cancer-type/other-cancer-types","siteSpaceId":"sitesp_Rf4YD","description":"Additional mebendazole oncology evidence across melanoma, pancreatic, colorectal, breast, and other cancer models","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"},{"label":"Mebendazole Evidence by Cancer Type"}]},{"id":"MM1ZlbpQgVr8JCgNEpRK","title":"Immune Effects","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How mebendazole may support anti-tumour immune responses through its unusual ERK-related effects","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"kIES8dLjV9qgvH642IBx","title":"Pharmacokinetics & Dosing","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/pharmacokinetics-and-dosing","siteSpaceId":"sitesp_Rf4YD","description":"Mebendazole dosing, tolerated ranges, pharmacokinetics, and practical clinical considerations in oncology use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"QXaiMJATLMFYPJvQH4ei","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Safety profile, tolerability, and practical interaction considerations for repurposed mebendazole in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"0exNIfjZpMIzUS577yek","title":"Sourcing Quality Mebendazole","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/sourcing-quality-mebendazole","siteSpaceId":"sitesp_Rf4YD","description":"Under construction — sourcing, formulation, access, and practical purchasing considerations for mebendazole in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Mebendazole in Oncology"}]},{"id":"hMxmuxVZ9aDySYXLIU7q","title":"Itraconazole in Oncology","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology","siteSpaceId":"sitesp_Rf4YD","description":"Deep-dive guide to itraconazole in oncology, including mechanisms, cancer-type evidence, dosing, safety, and sourcing","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"}]},{"id":"Z5BHYECrRGXC3IVRHzr3","title":"Itraconazole Overview","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-overview","siteSpaceId":"sitesp_Rf4YD","description":"What itraconazole is, why it is being repurposed in oncology, and where the evidence is strongest","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"}]},{"id":"vdWEhVdNk0JSBjoPQSrP","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of itraconazole in oncology, including strengths, limitations, clinical positioning, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"}]},{"id":"jkj7qws9cydBZZxf2pxz","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of itraconazole and why it is a serious repurposing candidate","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"}]},{"id":"Vl1hcmIoXa1UUT3HIBUZ","title":"Itraconazole Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to itraconazole in oncology, including prostate, lung, basal cell, ovarian, breast, pancreatic, and related research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"}]},{"id":"7WC8k5AIWXBbSVRIapVx","title":"Prostate Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of itraconazole in metastatic castration-resistant prostate cancer and Hedgehog-related treatment logic","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"},{"label":"Itraconazole Evidence by Cancer Type"}]},{"id":"gCPDDgw435aELxe2rQfN","title":"Non-Small Cell Lung Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/non-small-cell-lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of itraconazole in NSCLC, including pemetrexed combination data and angiogenesis relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"},{"label":"Itraconazole Evidence by Cancer Type"}]},{"id":"6GvTesm1n7qTdwYhnB1P","title":"Basal Cell Carcinoma","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/basal-cell-carcinoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of itraconazole in basal cell carcinoma and Hedgehog-pathway relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"},{"label":"Itraconazole Evidence by Cancer Type"}]},{"id":"VGkTvgEJkZKkXe2INOEZ","title":"Ovarian Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/ovarian-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of itraconazole in ovarian clear cell carcinoma and chemotherapy-combination settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"},{"label":"Itraconazole Evidence by Cancer Type"}]},{"id":"DL2t9XoOmoTvHOGAjn4C","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of itraconazole in metastatic triple-negative breast cancer, including early clinical signal and anti-angiogenic biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"},{"label":"Itraconazole Evidence by Cancer Type"}]},{"id":"LfCHNjv8oE0aRkdDASig","title":"Pancreatic Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of itraconazole in recurrent pancreatic cancer and chemotherapy-combination settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"},{"label":"Itraconazole Evidence by Cancer Type"}]},{"id":"0ptBJP9DAMG3wQU4hdVl","title":"Other Cancer Types","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/itraconazole-evidence-by-cancer-type/other-cancer-types","siteSpaceId":"sitesp_Rf4YD","description":"Additional itraconazole oncology evidence across Hedgehog-driven, angiogenesis-driven, and resistant tumour settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"},{"label":"Itraconazole Evidence by Cancer Type"}]},{"id":"MBIPSiZkpNtRpL3rxlEN","title":"Pharmacokinetics & Dosing","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/pharmacokinetics-and-dosing","siteSpaceId":"sitesp_Rf4YD","description":"Itraconazole dosing, repurposed-use ranges, and practical pharmacokinetic considerations in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"}]},{"id":"YQ9RC7JStzIBg8neqaaL","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Safety profile, hepatic and cardiac cautions, and practical interaction considerations for itraconazole in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"}]},{"id":"JmmEFzSRJUzbyfy3HMdL","title":"Sourcing Quality Itraconazole","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/itraconazole-in-oncology/sourcing-quality-itraconazole","siteSpaceId":"sitesp_Rf4YD","description":"Under construction — sourcing, access, formulation, and practical purchasing considerations for itraconazole in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Itraconazole in Oncology"}]},{"id":"TFTGVfSfMALh461KSW5f","title":"Ivermectin in Cancer: a checklist for patients","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/ivermectin-in-cancer-a-checklist-for-patients","siteSpaceId":"sitesp_Rf4YD","description":"Ivermectin in cancer: a simple checklist for a more informed look","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"}]},{"id":"ht1S5u5BURK7GzM2Qj1v","title":"Aspirin in Oncology","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology","siteSpaceId":"sitesp_Rf4YD","description":"Deep-dive guide to aspirin in oncology, including mechanisms, cancer-type evidence, dosing, safety, and immune relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"}]},{"id":"olH4NnjJGWRZYrw3Lbcm","title":"Aspirin Overview","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-overview","siteSpaceId":"sitesp_Rf4YD","description":"What aspirin is, why it is studied in oncology, and where the evidence is strongest","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"hcEpmkjkUOAVUNMUbQxa","title":"Aspirin-Like Compounds","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-like-compounds","siteSpaceId":"sitesp_Rf4YD","description":"How willow bark, dipyridamole, and cayenne or capsaicin compare with aspirin in platelet biology and oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"jis1d3blgAIBhm7wqXjZ","title":"Evidence Summary","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/evidence-summary","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based summary of aspirin in oncology, including strengths, limitations, clinical positioning, and treatment considerations","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"tsC4eLkDX6SvF9OiPZRf","title":"Anticancer Mechanisms","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Primary anti-cancer mechanisms of aspirin and why it remains a serious repurposing candidate","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"mSvUTUX7YAgg2BH1Z7RZ","title":"Aspirin and Thromboxane A2 (TXA2)","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/anticancer-mechanisms/aspirin-and-thromboxane-a2-txa2","siteSpaceId":"sitesp_Rf4YD","description":"Why platelet-derived TXA2 matters in metastasis, immune evasion, and aspirin's anti-metastatic profile","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Anticancer Mechanisms"}]},{"id":"pEKxMcG2Kz4n5B2eHlFo","title":"Aspirin Evidence by Cancer Type","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type","siteSpaceId":"sitesp_Rf4YD","description":"Cancer-type guide to aspirin in oncology, including major solid tumours, myelofibrosis, and related research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"u7RFo5ViPdn7QEkVCThc","title":"Colorectal Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/colorectal-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in colorectal cancer, including PIK3CA-selected trial data, Lynch syndrome relevance, and anti-metastatic findings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"JdXl9vIXaBrMAfuQwWal","title":"Breast Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in breast cancer, including the negative Phase 3 trial, observational recurrence signals, PIK3CA relevance, and TXA2 biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"Gt328sufx8NQiyDsg45J","title":"Gastric Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/gastric-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in gastric cancer, including inflammation-related rationale, GI relevance, and current evidence limits","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"yvluByQ8vBbePS7gP7ud","title":"Lung Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/lung-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in lung cancer, including observational signals, anti-metastatic logic, and current evidence limits","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"K28mNh0PSv1YhqzzBCKH","title":"Endometrial Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/endometrial-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in endometrial cancer, including frequency-dependent prevention signals, obesity-linked biology, and supportive survival data","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"t0Sy6hjPFhNfuzlno5in","title":"Ovarian Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/ovarian-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in ovarian cancer, including pooled prevention data, histotype-specific signals, and current evidence limits","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"Tk12njVdZGAVo840XOQA","title":"Pancreatic Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/pancreatic-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in pancreatic cancer, including strong prevention signals, diabetes-linked risk reduction, and platelet biology relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"AYrtpAUyp3yS0evJo5Cu","title":"Glioblastoma","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/glioblastoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in glioblastoma, including stem-cell targeting, temozolomide sensitisation, angiogenesis inhibition, and BBB-delivery limits","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"niBuSDG4pqpg2AZbhNZ3","title":"Osteosarcoma","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/osteosarcoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in osteosarcoma, including lung-metastasis suppression, cisplatin sensitisation, NF-κB biology, and emerging PDE4D relevance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"hdmRFiAUKOPZnE0IvFj4","title":"Prostate Cancer","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in prostate cancer, including prevention, post-diagnosis survival, post-surgical recurrence data, and biomarker-defined subgroups","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"3cUrfLfl2qW9aWvNsQna","title":"Liver Cancer (Hepatocellular Carcinoma)","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/liver-cancer-hepatocellular-carcinoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in hepatocellular carcinoma, including chronic liver disease prevention, duration-dependent benefit, MASLD relevance, and the Australian NHMRC trial","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"dtOFFyyrMd8rtLSM87aM","title":"Melanoma","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/melanoma","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in melanoma, including prevention, immunotherapy-combination logic, platelet biology, and the critical high-dose Phase 2 lesson","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"MSncYahLF06Bs9EuDGKT","title":"Myelofibrosis","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/myelofibrosis","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of aspirin in myelofibrosis, including thrombosis prevention, MPN dosing issues, JAK-STAT and NF-κB overlap, and the current anti-fibrotic evidence gap","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"1q6hEzfI2rtVQERA4Q5F","title":"Other Cancer Types","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/aspirin-evidence-by-cancer-type/other-cancer-types","siteSpaceId":"sitesp_Rf4YD","description":"Short evidence summaries for additional aspirin cancer signals, including bladder cancer, lymphoma subtypes, cervical cancer, and important cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"},{"label":"Aspirin Evidence by Cancer Type"}]},{"id":"W6KamvDX8iGbqWVo5EiP","title":"Pharmacokinetics & Dosing","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/pharmacokinetics-and-dosing","siteSpaceId":"sitesp_Rf4YD","description":"Aspirin dosing context, low-dose use patterns, and practical pharmacokinetic considerations in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"NhWlbRKcPncnucbq8XYq","title":"Safety & Interactions","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/safety-and-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Safety profile, bleeding risk, interaction cautions, and practical oncology considerations for aspirin","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"5ZLnqM5DRcChpRNJW9dJ","title":"Sourcing Quality Aspirin","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/sourcing-quality-aspirin","siteSpaceId":"sitesp_Rf4YD","description":"How to judge aspirin formulation, dose, access, storage, and product quality for oncology-oriented use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"hzWp5giczY0dvhns6FaI","title":"Immune Effects","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/aspirin-in-oncology/immune-effects","siteSpaceId":"sitesp_Rf4YD","description":"How aspirin may support anti-tumour immune activity through platelet and tumour-microenvironment effects","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"},{"label":"Aspirin in Oncology"}]},{"id":"t2eryP9qfzPhgAdDLkkO","title":"Off-Label and Re-Purposed Drugs Study Support Threads A–Z","pathname":"/myhealingcommunity-docs/off-label-drugs-for-cancer/off-label-and-re-purposed-drugs-study-support-threads-a-z","siteSpaceId":"sitesp_Rf4YD","description":"A–Z index of Healing Cancer Study Support Group conversation threads and file links for off-label and repurposed drugs","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Off-Label Drugs for Cancer"}]},{"id":"pTPMndoVBHhY1kHhZ3DC","title":"Breast Cancers Overview","pathname":"/myhealingcommunity-docs/breast-cancer/breast-cancers-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of the breast-cancer space, including subtype hubs and shared cross-subtype topics","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"lNzPgmvfos6Ti81Qw7PP","title":"HER2-Positive","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"Ej2bjpEjREDXZKe6co8S","title":"HER2CLIMB","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"}]},{"id":"d86q8BQtRl0UXqszAoMh","title":"HER2CLIMB Guide","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/her2climb-guide","siteSpaceId":"sitesp_Rf4YD","description":"Central guide to HER2CLIMB resistance, testing, tucatinib clearance, and supplement-interaction pages across the site","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"},{"label":"HER2CLIMB"}]},{"id":"7jbULIbxrp4DozQLusJR","title":"HER2CLIMB Resistance Mechanisms","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/her2climb-resistance-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"Possible molecular and clinical mechanisms that may drive progression on the tucatinib, trastuzumab, and capecitabine regimen","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"},{"label":"HER2CLIMB"}]},{"id":"xAab9faJodhTnMlBZK2l","title":"Liquid Biopsy for HER2-Positive Resistance","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/liquid-biopsy-for-her2-positive-resistance","siteSpaceId":"sitesp_Rf4YD","description":"How ctDNA testing may help identify resistance mechanisms in HER2-positive breast cancer, including after tucatinib-based therapy","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"},{"label":"HER2CLIMB"}]},{"id":"pbp8TfulVBJ9qf1biRND","title":"Tucatinib Clearance, Genetics, and Enzyme Inducers","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/tucatinib-clearance-genetics-and-enzyme-inducers","siteSpaceId":"sitesp_Rf4YD","description":"How CYP3A4, CYP2C8, genetic variation, and enzyme inducers may affect tucatinib exposure in the HER2CLIMB setting","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"},{"label":"HER2CLIMB"}]},{"id":"4uCeWmGvG7GknhCO2Q5I","title":"Natural Compounds and CYP3A4 — HER2CLIMB Considerations","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/natural-compounds-and-cyp3a4-her2climb-considerations","siteSpaceId":"sitesp_Rf4YD","description":"Practical overview of how commonly used supplements may affect CYP3A4 in the tucatinib-based HER2CLIMB regimen","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"},{"label":"HER2CLIMB"}]},{"id":"9Lf0PUOqrlifKlkiwnLs","title":"Enhertu, Senescence, and the Senolytic Second Strike","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/enhertu-senescence-and-the-senolytic-second-strike","siteSpaceId":"sitesp_Rf4YD","description":"How trastuzumab deruxtecan interacts with cellular senescence and dormancy — and why a timed senolytic strategy may matter after each cycle.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"}]},{"id":"5vN2issRrvakgFDpUaUu","title":"Should HER2+/ERα+ Patients Avoid Resveratrol or Polydatin?","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/should-her2+-era+-patients-avoid-resveratrol-or-polydatin","siteSpaceId":"sitesp_Rf4YD","description":"Research note on the caution around resveratrol or polydatin in Luminal B HER2-positive, ERα-positive breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"}]},{"id":"cMEl4ftvyoZXPXBEJA4C","title":"HER2+ Breast Cancer – Integrative Protocols","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/her2+-breast-cancer-integrative-protocols","siteSpaceId":"sitesp_Rf4YD","description":"Group and support resource notes for HER2-positive breast-cancer patients exploring integrative protocols","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"}]},{"id":"mll8BewFdo5gmDNgmlNi","title":"Support Threads & Docs","pathname":"/myhealingcommunity-docs/breast-cancer/her2-positive/support-threads-and-docs","siteSpaceId":"sitesp_Rf4YD","description":"Facebook study-support threads and Google Doc links relevant to HER2-positive breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"HER2-Positive"}]},{"id":"uav4AkwqKdRqBkcfDIQc","title":"ER-Positive / HER2-Negative","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative","siteSpaceId":"sitesp_Rf4YD","description":"Estrogen-receptor-positive/HER2-negative breast cancer research summaries that need their own treatment and resistance contexts.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"UCCZ8FKXNO2rt6dYBrjd","title":"New BCL‑2 Inhibitor Trial in HR+ MBC – and Why Whack-a-Mole Still Matters","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/new-bcl-2-inhibitor-trial-in-hr+-mbc-and-why-whack-a-mole-still-matters","siteSpaceId":"sitesp_Rf4YD","description":"This trial is exciting because it is a much more direct attempt to force cancer cells into apoptosis than any standard of care ER+ therapy has attempted.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"ncsCrpE29LsB0iSnkuiX","title":"Endocrine therapy, resistance, and dormancy","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"tFemjK8whMoHF7qU4Bex","title":"CDK4/6 Options and Supplement Considerations","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations","siteSpaceId":"sitesp_Rf4YD","description":"Balanced look at palbociclib, ribociclib, and abemaciclib in HR-positive disease, including supplement considerations and monitoring questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"}]},{"id":"tWkF0EdLIODZd8NZyJEF","title":"SONIA Trial and CDK4/6 Timing","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations/sonia-trial-and-cdk4-6-timing","siteSpaceId":"sitesp_Rf4YD","description":"What the SONIA phase 3 trial suggests about first-line versus second-line CDK4/6 inhibitor sequencing in HR-positive, HER2-negative advanced breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"CDK4/6 Options and Supplement Considerations"}]},{"id":"TlmfvDOafEqYWPQdn010","title":"Galectin‑3, Cyclin D1, Modified Citrus Pectin(MCP) and CDK4/6: A Patient Guide","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/cdk4-6-options-and-supplement-considerations/galectin-3-cyclin-d1-modified-citrus-pectin-mcp-and-cdk4-6-a-patient-guide","siteSpaceId":"sitesp_Rf4YD","description":"This page explains how galectin‑3 (Gal‑3) connects to the same cell‑cycle pathway targeted by CDK4/6 inhibitors, and why people are talking about MCP and diet.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"CDK4/6 Options and Supplement Considerations"}]},{"id":"MKjNTVo6Qc6Ci8E8TfC5","title":"Autophagy Escape in ER-Positive Breast Cancer","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-escape-in-er-positive-breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Why mTOR pressure, glycolysis, PI3K inhibition, dormancy, and hydroxychloroquine come up in ER-positive/HER2-negative disease, with or without known TP53 status","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"}]},{"id":"AdLu0CYieYQsbc077eAb","title":"Autophagy and Senescence in Antiestrogen Resistance","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance","siteSpaceId":"sitesp_Rf4YD","description":"Plain-language guide to the 2024 review on how autophagy and reversible senescence may help ER-positive breast cancer survive endocrine therapy and CDK4/6 pressure","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"}]},{"id":"qTvHuLbNvWWXiLPpdntq","title":"Overview and key takeaways","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance/overview-and-key-takeaways","siteSpaceId":"sitesp_Rf4YD","description":"Plain-language overview of why autophagy and reversible senescence matter in ER-positive antiestrogen resistance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"Autophagy and Senescence in Antiestrogen Resistance"}]},{"id":"PyKtCM02gZli4otxNdSW","title":"Endocrine therapy, CDK4/6, and why resistance still happens","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance/endocrine-therapy-cdk4-6-and-why-resistance-still-happens","siteSpaceId":"sitesp_Rf4YD","description":"How ER-positive treatments work, where they help most, and why many cancers still find a way to survive","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"Autophagy and Senescence in Antiestrogen Resistance"}]},{"id":"x4Lzg5b4GClCbrercv28","title":"Autophagy — the first escape route","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance/autophagy-the-first-escape-route","siteSpaceId":"sitesp_Rf4YD","description":"What autophagy is, how it works, and why it keeps showing up in ER-positive antiestrogen resistance","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"Autophagy and Senescence in Antiestrogen Resistance"}]},{"id":"a00mghcKoYcjLTQFMjqd","title":"Senescence — the second escape route","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance/senescence-the-second-escape-route","siteSpaceId":"sitesp_Rf4YD","description":"Why treatment-induced senescence can protect surviving cells, and why the review focuses on SASP and senolytics","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"Autophagy and Senescence in Antiestrogen Resistance"}]},{"id":"J8ks0F3piDsjt1SbB8Qg","title":"Established resistance mechanisms","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance/established-resistance-mechanisms","siteSpaceId":"sitesp_Rf4YD","description":"The main mutations and bypass pathways that may accumulate while ER-positive cells survive in autophagy or senescence","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"Autophagy and Senescence in Antiestrogen Resistance"}]},{"id":"r6IW4yxHd0whaRuvfGkX","title":"Glossary and trial notes","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/autophagy-and-senescence-in-antiestrogen-resistance/glossary-and-trial-notes","siteSpaceId":"sitesp_Rf4YD","description":"Quick definitions for the main terms in this review, plus the current hydroxychloroquine-based trial landscape","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"},{"label":"Autophagy and Senescence in Antiestrogen Resistance"}]},{"id":"qZBkyGusEt1gvUljogxj","title":"Endocrine Therapy, Stable Disease, and Dormancy in ER-Positive Breast Cancer","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/endocrine-therapy-stable-disease-and-dormancy-in-er-positive-breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Why endocrine therapy can help hold ER-positive breast cancer in a long quiet phase, and why late reactivation can still happen","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"}]},{"id":"4G3bCqXkoTPBfvI5PV0l","title":"Slow-Growing ER+ Breast Cancer Cells and How Rac-1 and The IGF Axis Supports Relapse","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/slow-growing-er+-breast-cancer-cells-and-how-rac-1-and-the-igf-axis-supports-relapse","siteSpaceId":"sitesp_Rf4YD","description":"A new ER+ breast cancer paper shows that some cells survive therapy by going slow, entering a senescent‑like state and wiring in a Rac1–IGF‑axis survival circuit that supports late relapse.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"}]},{"id":"igwvJkFB63DY8zLZNHvi","title":"AI Resistance and the 4-OHE1/E2 Pathway","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/ai-resistance-and-the-4-ohe1-e2-pathway","siteSpaceId":"sitesp_Rf4YD","description":"How 4-OHE1/E2 handling, methylation, glutathione support, elimination, and melatonin may affect aromatase-inhibitor resistance pressure","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"}]},{"id":"64LTkm44x8ru5ZMGPEd5","title":"Blood Biopsy Trial — Getting Ahead of Treatment Resistance","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/endocrine-therapy-resistance-and-dormancy/blood-biopsy-trial-getting-ahead-of-treatment-resistance","siteSpaceId":"sitesp_Rf4YD","description":"How ctDNA testing and early ESR1 detection may help guide earlier treatment switching in HR-positive, HER2-negative metastatic breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"},{"label":"Endocrine therapy, resistance, and dormancy"}]},{"id":"I6CgMTJcKTwIC1stCcbc","title":"Letrozole Side Effects and Possible Considerations","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/letrozole-side-effects-and-possible-considerations","siteSpaceId":"sitesp_Rf4YD","description":"Side-effect notes and practical considerations for people using letrozole in HR-positive breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"YHBGxu0T7g59jeTVwJBL","title":"COMT Status and Tamoxifen","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/comt-status-and-tamoxifen","siteSpaceId":"sitesp_Rf4YD","description":"The crucial COMT-Tamoxifen connection in ER+ breast cancer treatment.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"HtYYdVmUzfv5mq3EgRAc","title":"ER+/PR- Receptor Status","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/er+-pr-receptor-status","siteSpaceId":"sitesp_Rf4YD","description":"Research and support notes on what ER-positive, PR-negative receptor status may mean in breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"f6JIGzpxvu5Afn5kMMLz","title":"Distinguishing Luminal A from Luminal B","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/distinguishing-luminal-a-from-luminal-b","siteSpaceId":"sitesp_Rf4YD","description":"Plain-language notes on the difference between Luminal A and Luminal B breast cancer and why the distinction matters","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"jVpNKsIoVbYV65M9u0FK","title":"AR+/ER+ Breast Cancer","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/ar+-er+-breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Deep dive on androgen-receptor-positive, estrogen-receptor-positive breast cancer, including AR-dominant biology, enobosarm logic, resistance questions, and monitoring ideas","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"SsAbvabBSlNqpWGFMYtk","title":"Fulvestrant and the Keto Diet","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/fulvestrant-and-the-keto-diet","siteSpaceId":"sitesp_Rf4YD","description":"Research notes on fulvestrant, metabolic context, and the ketogenic-diet question in HR-positive breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"LisrnWimG1HK9bLtMCP3","title":"Genistein Dosing in ER-Positive Breast Cancer","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/genistein-dosing-in-er-positive-breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Research notes on genistein dosing questions in estrogen-receptor-positive breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"uFuingsl61QlY22g74tS","title":"Quercetin Notes on ER+ and Aromatase Modulation","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/quercetin-notes-on-er+-and-aromatase-modulation","siteSpaceId":"sitesp_Rf4YD","description":"Notes on quercetin in ER-positive breast cancer, including dose dependency, COMT activity, and aromatase questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"6WxsVkFfvXckwiOahMXA","title":"Gilbert Syndrome, UGT1A1, and Estrogen Detox","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/gilbert-syndrome-ugt1a1-and-estrogen-detox","siteSpaceId":"sitesp_Rf4YD","description":"Research and support notes on Gilbert syndrome, UGT1A1, and estrogen-handling questions in breast-cancer context","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"HFyCxgO8AwPY2OsUz3fY","title":"Androgen Modulation's Role in Healing Breast Cancer","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/androgen-modulations-role-in-healing-breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Notes on androgen modulation and why it may matter in breast-cancer healing and support discussions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"oauiSnU0XdFb1DiY90Sy","title":"Support Threads & Docs","pathname":"/myhealingcommunity-docs/breast-cancer/er-positive-her2-negative/support-threads-and-docs","siteSpaceId":"sitesp_Rf4YD","description":"Facebook study-support threads and Google Doc links that apply across breast-cancer subtypes or to broader breast-cancer questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"ER-Positive / HER2-Negative"}]},{"id":"yrkC5hQZYoFoeMXLQuAC","title":"Ivermectin & ER+ Breast Cancer: What the 2026 Research Actually Found","pathname":"/myhealingcommunity-docs/breast-cancer/ivermectin-and-er+-breast-cancer-what-the-2026-research-actually-found","siteSpaceId":"sitesp_Rf4YD","description":"Plain-language breakdown of the 2026 ER-positive breast-cancer study showing ivermectin effects on ESR1/ERα, HER2, TGF-β signalling, and tamoxifen synergy","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"V7sRDgFtDnWR0Ra2ffW3","title":"Triple-Positive","pathname":"/myhealingcommunity-docs/breast-cancer/triple-positive","siteSpaceId":"sitesp_Rf4YD","description":"Overview of triple-positive breast cancer, including what it is and where relevant support threads and overlapping subtype resources currently live","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"Ovdd8jENLlyxE3LJRAFl","title":"Triple-Negative","pathname":"/myhealingcommunity-docs/breast-cancer/triple-negative","siteSpaceId":"sitesp_Rf4YD","description":"Overview of triple-negative breast cancer, including biomarkers, standard treatment logic, and common drug names used in this section","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"OeYUFtydMEPy4ihz4j4O","title":"LAR-Subtype Triple-Negative (AR-Positive)","pathname":"/myhealingcommunity-docs/breast-cancer/triple-negative/lar-subtype-triple-negative-ar-positive","siteSpaceId":"sitesp_Rf4YD","description":"Patient guide to luminal androgen receptor TNBC, including biomarkers, trial directions, and supportive research themes","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Triple-Negative"}]},{"id":"AqasVEAH4OFRzw3zDRlj","title":"Treatment Resistance Research","pathname":"/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research","siteSpaceId":"sitesp_Rf4YD","description":"Guide to the TNBC resistance section, including natural compounds, repurposed drugs, and emerging resistance-strategy pages","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Triple-Negative"}]},{"id":"laizfYOi3PsjjToF31Nb","title":"TNBC Natural Compounds in Treatment Resistance Research","pathname":"/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-natural-compounds-in-treatment-resistance-research","siteSpaceId":"sitesp_Rf4YD","description":"Research notes on natural compounds being explored to counter treatment resistance in triple-negative breast cancer, including pterostilbene, blueberries, and piperlongumine","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Triple-Negative"},{"label":"Treatment Resistance Research"}]},{"id":"WmxCzOz1nOhcLJzWA7zV","title":"TNBC Off-Label Drugs in Treatment Resistance Research","pathname":"/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/tnbc-off-label-drugs-in-treatment-resistance-research","siteSpaceId":"sitesp_Rf4YD","description":"Research notes on repurposed off-label drugs being explored to counter treatment resistance in triple-negative breast cancer, including pitavastatin, melatonin, and metformin","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Triple-Negative"},{"label":"Treatment Resistance Research"}]},{"id":"6szWaj3fOKwK8att1MdQ","title":"Emerging Resistance Strategies","pathname":"/myhealingcommunity-docs/breast-cancer/triple-negative/treatment-resistance-research/emerging-resistance-strategies","siteSpaceId":"sitesp_Rf4YD","description":"Deeper look at RNA-targeting and multi-target combination strategies being explored for treatment-resistant triple-negative breast cancer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Triple-Negative"},{"label":"Treatment Resistance Research"}]},{"id":"retixXel72wbobe11CVV","title":"Post-Chemotherapy Cell Senescence Clean-up","pathname":"/myhealingcommunity-docs/breast-cancer/post-chemotherapy-cell-senescence-clean-up","siteSpaceId":"sitesp_Rf4YD","description":"Study notes on post-chemotherapy senescence, lingering treatment effects, and the idea of senescent-cell clean-up in breast-cancer context","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"l28P0C9uCjTcwQAx4qIf","title":"Dormant Cancer Cells: How to Erase Them","pathname":"/myhealingcommunity-docs/breast-cancer/dormant-cancer-cells-how-to-erase-them","siteSpaceId":"sitesp_Rf4YD","description":"Study summary on breast-cancer dormancy, persistence, and the idea of targeting dormant cells","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"Auoac6Hn2qlyLwUooLrb","title":"Lactoferrin Warning in Breast Cancer","pathname":"/myhealingcommunity-docs/breast-cancer/lactoferrin-warning-in-breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Research notes on higher-dose lactoferrin and why it raises caution questions in breast-cancer settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"fA4qLqXja7HbtCLQGV1u","title":"Collagen When Healing Breast Cancer","pathname":"/myhealingcommunity-docs/breast-cancer/collagen-when-healing-breast-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Research notes on collagen in breast-cancer healing, tissue repair, and the questions this raises in treatment and recovery context","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"zUClHquUALoyuQ9AzvAp","title":"Radiation Post-First-Line Chemo? 2025 Summary","pathname":"/myhealingcommunity-docs/breast-cancer/radiation-post-first-line-chemo-2025-summary","siteSpaceId":"sitesp_Rf4YD","description":"Research summary on using radiation after first-line chemotherapy and how to think through that choice in breast-cancer context","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"GRPNKtrQCmdljtdIuGkm","title":"Support Threads & Docs","pathname":"/myhealingcommunity-docs/breast-cancer/support-threads-and-docs","siteSpaceId":"sitesp_Rf4YD","description":"Facebook study-support threads and Google Doc links that apply across breast-cancer subtypes or to less subtype-specific breast-cancer questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"Gqozc8qwuphbjzYm0O7H","title":"Support Groups","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups","siteSpaceId":"sitesp_Rf4YD","description":"Groups, downloads, and community resources linked to breast-cancer research and support","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"}]},{"id":"STMCWbbDnsykCs2wW11N","title":"Breast Cancer Pathways Project","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups/breast-cancer-pathways-project","siteSpaceId":"sitesp_Rf4YD","description":"Breast cancer pathways worksheets, download guidance, support links, and getting-started pages","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Support Groups"}]},{"id":"uxVsyWAEdkQOlyDKSIp4","title":"Getting Started","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups/breast-cancer-pathways-project/getting-started","siteSpaceId":"sitesp_Rf4YD","description":"Step-by-step guide to using the Breast Cancer Pathways Project worksheet","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Support Groups"},{"label":"Breast Cancer Pathways Project"}]},{"id":"B3reRPRs6DGYeIq9aQBw","title":"Step 1 — Download the Worksheet","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups/breast-cancer-pathways-project/step-1-download-the-worksheet","siteSpaceId":"sitesp_Rf4YD","description":"How to download, copy, rename, and safely save your worksheet","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Support Groups"},{"label":"Breast Cancer Pathways Project"}]},{"id":"dFRyN8XvdOq9McXGLkLG","title":"Step 2 — Explore Your Worksheet","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups/breast-cancer-pathways-project/step-2-explore-your-worksheet","siteSpaceId":"sitesp_Rf4YD","description":"How to navigate tabs, understand the worksheet structure, and avoid editing the wrong fields","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Support Groups"},{"label":"Breast Cancer Pathways Project"}]},{"id":"JYNLZwHt8iZN9bDCspsW","title":"Step 3 — Standard of Care Choices","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups/breast-cancer-pathways-project/step-3-standard-of-care-choices","siteSpaceId":"sitesp_Rf4YD","description":"How to enter conventional treatment choices so the worksheet can populate the relevant sections","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Support Groups"},{"label":"Breast Cancer Pathways Project"}]},{"id":"2bSTOupPmbJ32IRPNSOW","title":"Step 4 — Typical Dosages","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups/breast-cancer-pathways-project/step-4-typical-dosages","siteSpaceId":"sitesp_Rf4YD","description":"How to interpret the worksheet dosage guidance safely and in context","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Support Groups"},{"label":"Breast Cancer Pathways Project"}]},{"id":"38G9O2YRW7SaXySOnvSm","title":"Step 5 — Sharing Your Worksheet","pathname":"/myhealingcommunity-docs/breast-cancer/support-groups/breast-cancer-pathways-project/step-5-sharing-your-worksheet","siteSpaceId":"sitesp_Rf4YD","description":"How to share your worksheet with practitioners, supporters, or community resources","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Breast Cancer"},{"label":"Support Groups"},{"label":"Breast Cancer Pathways Project"}]},{"id":"y2L6XLjsuXDeSoZHp3aL","title":"Cancer Patient Community Supports Overview","pathname":"/myhealingcommunity-docs/cancer-patient-community-supports/cancer-patient-community-supports-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of cancer patient community supports, including books, podcasts, groups, and practical support resources","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Patient Community Supports"}]},{"id":"kcyQPfLE9j0RtsTLs1NX","title":"Free Podcasts","pathname":"/myhealingcommunity-docs/cancer-patient-community-supports/free-podcasts","siteSpaceId":"sitesp_Rf4YD","description":"Free podcast resources for cancer patients, carers, and integrative oncology learners","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Patient Community Supports"}]},{"id":"mYLaDYzlXEgy08IyfkeC","title":"Books","pathname":"/myhealingcommunity-docs/cancer-patient-community-supports/books","siteSpaceId":"sitesp_Rf4YD","description":"Book recommendations and reading resources for cancer patients and supportive learning","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Patient Community Supports"}]},{"id":"Zz0lEDHE8kKwSd5LiJ9Z","title":"Cancer Type Support and Discussion Threads A–Z","pathname":"/myhealingcommunity-docs/cancer-patient-community-supports/cancer-type-support-and-discussion-threads-a-z","siteSpaceId":"sitesp_Rf4YD","description":"A–Z index of Healing Cancer Study Support Group discussion threads organised by cancer type","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Patient Community Supports"}]},{"id":"LMEVsQamGttUIfssfWL2","title":"About Abbey the Founder","pathname":"/myhealingcommunity-docs/cancer-patient-community-supports/about-abbey-the-founder","siteSpaceId":"sitesp_Rf4YD","description":"Background, lived experience, and community work behind My Healing Community","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Patient Community Supports"}]},{"id":"jEgHcL7XsZAMcvLhMuOc","title":"Trusted Suppliers and Discounts","pathname":"/myhealingcommunity-docs/cancer-patient-community-supports/trusted-suppliers-and-discounts","siteSpaceId":"sitesp_Rf4YD","description":"Why MCS Formulas is featured here, how the abbey5 code helps, and the full A–Z product list in one place","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Cancer Patient Community Supports"}]},{"id":"qXpQIIlYvZs4yjvngdEn","title":"Pathogens Overview","pathname":"/myhealingcommunity-docs/pathogens/pathogens-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of the pathogen library, including fungal, microbial, and viral sections","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"}]},{"id":"gf0b5l6DyZvy3eh2IkL8","title":"Microbial Pathogens","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens","siteSpaceId":"sitesp_Rf4YD","emoji":"1f9eb","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"}]},{"id":"9TetP8IFg0lZGDFrVHmk","title":"Fusobacterium nucleatum (Fn)","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"}]},{"id":"Fx7o8C2PQFcVxDSPNK3G","title":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"}]},{"id":"UQB3sGJBtShSF8vdeCJH","title":"Overview","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of Fusobacterium nucleatum as an oncology-relevant microbial factor, including tumour targeting, metastasis, and practical source control","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"u4a62YpzwJuKcbMCSKxc","title":"Why Oral Health Is an Oncology Issue Right Now","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/why-oral-health-is-an-oncology-issue-right-now","siteSpaceId":"sitesp_Rf4YD","description":"Why oral Fusobacterium nucleatum burden matters in cancer care, including periodontal disease, root-canal source control, and practical dental steps","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"LGecmH6ZPKvysgaZdASp","title":"How Fusobacterium nucleatum Travels Through the Body and Finds Tumours","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/how-fusobacterium-nucleatum-travels-through-the-body-and-finds-tumours","siteSpaceId":"sitesp_Rf4YD","description":"How Fusobacterium nucleatum enters circulation, homes to tumours, and may influence metastatic progression across multiple cancer settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"XUkMcb1mgW83f5uXcA88","title":"The Gut Microbiome — Reducing Fusobacterium nucleatum's Foothold Below the Stomach","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/the-gut-microbiome-reducing-fusobacterium-nucleatums-foothold-below-the-stomach","siteSpaceId":"sitesp_Rf4YD","description":"How gut ecology, diet, barrier integrity, and microbiome support may help reduce Fusobacterium nucleatum pressure in cancer settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"Tanq35xJWFNUZiPv9Fjv","title":"Targeted Antimicrobial Drugs in Oncology","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/targeted-antimicrobial-drugs-in-oncology","siteSpaceId":"sitesp_Rf4YD","description":"What the evidence suggests about metronidazole, 5-FU, and targeted antimicrobial pressure against Fusobacterium nucleatum in cancer settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"cEvFUIhkOD9VAqAXA7ID","title":"Berberine — The Most Studied Natural Compound With Direct Anti-Fusobacterium nucleatum Activity","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/berberine-the-most-studied-natural-compound-with-direct-anti-fusobacterium-nucleatum-activity","siteSpaceId":"sitesp_Rf4YD","description":"Why berberine stands out in the Fusobacterium nucleatum literature, including tumour-microenvironment effects, pathway overlap, and interaction cautions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"zs7zsOSteDOHHzVOopmO","title":"Green Tea EGCG and Dietary Polyphenols — Blocking Fusobacterium nucleatum at the Biofilm Level","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/green-tea-egcg-and-dietary-polyphenols-blocking-fusobacterium-nucleatum-at-the-biofilm-level","siteSpaceId":"sitesp_Rf4YD","description":"How EGCG, quercetin, and curcumin may affect Fusobacterium nucleatum biofilm, adhesion, and inflammatory signalling","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"HHnAhKnCybvR4HAQb3Nb","title":"Lactobacillus reuteri — Your Most Targeted Natural Counter to Fusobacterium nucleatum","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/lactobacillus-reuteri-your-most-targeted-natural-counter-to-fusobacterium-nucleatum","siteSpaceId":"sitesp_Rf4YD","description":"Why L. reuteri stands out in the Fusobacterium nucleatum literature, including coaggregation, biofilm disruption, and yoghurt-versus-capsule logic","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"4fYDHs7T249BGjught4s","title":"Fusobacterium and Bone","pathname":"/myhealingcommunity-docs/pathogens/microbial-pathogens/fusobacterium-nucleatum-fn-a-powerful-oncobacterium/fusobacterium-and-bone","siteSpaceId":"sitesp_Rf4YD","description":"How Fusobacterium can persist in bone and bone-adjacent tissue, including osteomyelitis, chronic persistence, and practical implications","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"},{"label":"Microbial Pathogens","emoji":"1f9eb"},{"label":"Fusobacterium nucleatum (Fn) a Powerful Oncobacterium"}]},{"id":"Epfrj9PjC3N7qa4s0ivD","title":"Viral Pathogens","pathname":"/myhealingcommunity-docs/pathogens/viral-pathogens","siteSpaceId":"sitesp_Rf4YD","emoji":"1f9ec","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Pathogens","icon":"bug"}]},{"id":"LBDy2alL7q4a6Bf1ZvcY","title":"Fungal Pathogens Overview","pathname":"/myhealingcommunity-docs/fungal-pathogens/fungal-pathogens-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of the fungal-pathogen section, starting with the anti-fungal protocol-building worksheet","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"}]},{"id":"papRcQCqWAvZkQqJDkct","title":"Anti-fungal Protocol Building Support","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support","siteSpaceId":"sitesp_Rf4YD","emoji":"1f344","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"}]},{"id":"d4MW1ZsgipEf7gJizBgr","title":"Expected Timeline & What to Watch For","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/expected-timeline-and-what-to-watch-for","siteSpaceId":"sitesp_Rf4YD","description":"Typical phases of response, rest week logic, and what changes to expect over time","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"8FwKX6jI4eG78KjHqNyh","title":"The Problem","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/the-problem","siteSpaceId":"sitesp_Rf4YD","description":"Why fungal-pathogen support often needs more than a single intervention","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"lhOe0RixzY7m1BkCWw5z","title":"Core Strategy","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/core-strategy","siteSpaceId":"sitesp_Rf4YD","description":"The layered model used in the anti-fungal worksheet","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"BYt9uPxOpZENqU527tzk","title":"Laminarin","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/laminarin","siteSpaceId":"sitesp_Rf4YD","description":"Laminarin's place in the worksheet as a calming and support layer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"3BoWJJRZKl8TzI9Z64Om","title":"Usnea Tincture","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/usnea-tincture","siteSpaceId":"sitesp_Rf4YD","description":"Usnea tincture's role as a fungal-weakening layer in the anti-fungal guide","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"RM4Rk9viFVRr9B3QRyg9","title":"β-Glucanase Enzymes","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/v-glucanase-enzymes","siteSpaceId":"sitesp_Rf4YD","description":"Enzymes positioned to break down fungal biofilm in the worksheet","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"AjzHo5DW0qQbTKUWH35o","title":"Binders & Detox Support","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/binders-and-detox-support","siteSpaceId":"sitesp_Rf4YD","description":"The toxin-management and elimination layer used to help handle die-off in the worksheet","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"veHjc3m0ArpY63GnJr09","title":"Antifungal Medication","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/antifungal-medication","siteSpaceId":"sitesp_Rf4YD","description":"The direct-kill layer in the worksheet, paired with scripts and blood tests","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"nlvcqyQOejLZJYZqa134","title":"Daily Schedule","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/daily-schedule","siteSpaceId":"sitesp_Rf4YD","description":"Example daily timing, weekly cycling, and spacing rules for the anti-fungal guide","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"kORkCWpd74c58TuDZGkM","title":"Key Fungal Players","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/key-fungal-players","siteSpaceId":"sitesp_Rf4YD","description":"Core fungal patterns, why they matter, and how they change protocol design","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"xjyJ9Z8dlHB9Gm9aSmOo","title":"Monitoring & Safety Guidelines","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/monitoring-and-safety-guidelines","siteSpaceId":"sitesp_Rf4YD","description":"Lab monitoring, red flags, expected die-off, and practical safety support during the protocol","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"qle9HFd0ET7jgbZTLE6z","title":"Pathogen Blood Testing","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/pathogen-blood-testing","siteSpaceId":"sitesp_Rf4YD","description":"Direct detection, conventional fungal markers, and how blood testing can support the protocol","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"T3c3AunNKIr0odFhUu8V","title":"Q&A: Pathogen β-Glucans vs Supplement β-Glucans","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/q-and-a-pathogen-v-glucans-vs-supplement-v-glucans","siteSpaceId":"sitesp_Rf4YD","description":"Why pathogenic fungal β-glucans and supplement β-glucans are not the same signal in practice","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"LPt88zhVogbMy3H6VvVn","title":"Stool Testing for Fungal Pathogens","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/stool-testing-for-fungal-pathogens","siteSpaceId":"sitesp_Rf4YD","description":"Stool-testing options, interpretation, susceptibility, and how gut results can guide the protocol","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"rQKMVFAFKrEuFl7n4QSx","title":"Scientific References & Further Reading","pathname":"/myhealingcommunity-docs/fungal-pathogens/anti-fungal-protocol-building-support/scientific-references-and-further-reading","siteSpaceId":"sitesp_Rf4YD","description":"Core papers and further reading for laminarin, usnic acid, biofilms, antifungals, and fungal-cancer links","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Fungal Pathogens","emoji":"1f344"},{"label":"Anti-fungal Protocol Building Support","emoji":"1f344"}]},{"id":"nNfP2cIZswymk0bP32ci","title":"Side Effects Overview","pathname":"/myhealingcommunity-docs/side-effects/side-effects-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of side-effect, symptom-support, and recovery topics across cancer therapies","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"}]},{"id":"cuECEdYFWWH358Eoqjhj","title":"How to use this section","pathname":"/myhealingcommunity-docs/side-effects/how-to-use-this-section","siteSpaceId":"sitesp_Rf4YD","description":"How to navigate the side-effects section and choose the right page","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"}]},{"id":"xuxkmxWmrp4GllWN1kAL","title":"Constipation and Slow Gut Motility","pathname":"/myhealingcommunity-docs/side-effects/constipation-and-slow-gut-motility","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based deep dive on constipation and slow bowel transit in cancer care, including causes, red flags, standard management, and integrative support questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"}]},{"id":"RICQVIZuJBIbmTJKaQm3","title":"Cerebral Oedema, Brain Swelling, and Radiation Necrosis","pathname":"/myhealingcommunity-docs/side-effects/cerebral-oedema-brain-swelling-and-radiation-necrosis","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of cerebral oedema and radiation necrosis in cancer care, including what they are, why they matter, standard management, and why Boswellia is discussed in neuro-oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"}]},{"id":"sMNuonjUnzryh9wi9NaJ","title":"Neutropenia — Low White Blood Cell Count","pathname":"/myhealingcommunity-docs/side-effects/neutropenia-low-white-blood-cell-count","siteSpaceId":"sitesp_Rf4YD","emoji":"1f4d8","description":"Evidence-based deep dive on neutropenia in cancer care, including causes, monitoring, red flags, standard management, and integrative support questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"}]},{"id":"7LffDMMrWe1e0cwE7PGA","title":"Peripheral Neuropathy After Cancer Treatment","pathname":"/myhealingcommunity-docs/side-effects/peripheral-neuropathy-after-cancer-treatment","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based deep dive on treatment-related peripheral neuropathy, including causes, red flags, standard care, and integrative support questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"}]},{"id":"RhAt8C9RAUP76l4KFYVk","title":"Peripheral Neuropathy — Member Experiences","pathname":"/myhealingcommunity-docs/side-effects/peripheral-neuropathy-after-cancer-treatment/peripheral-neuropathy-member-experiences","siteSpaceId":"sitesp_Rf4YD","description":"Community-sourced lived experience and coping strategies for treatment-related peripheral neuropathy","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"},{"label":"Peripheral Neuropathy After Cancer Treatment"}]},{"id":"B2kYrO431yuCU4mBT2R6","title":"Alpha-Lipoic Acid","pathname":"/myhealingcommunity-docs/side-effects/peripheral-neuropathy-after-cancer-treatment/alpha-lipoic-acid","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of alpha-lipoic acid as a possible adjunct for peripheral neuropathy, including mechanisms, evidence limits, and safety notes","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Side Effects"},{"label":"Peripheral Neuropathy After Cancer Treatment"}]},{"id":"T0Lh9fAugbvOolyDBtAW","title":"Surgery Support; Before and After Care","pathname":"/myhealingcommunity-docs/surgery-support-before-and-after-care","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based perioperative guidance for cancer patients before and after surgery","breadcrumbs":[{"label":"Home","icon":"house"}]},{"id":"CO4xRyTGkzYTfR954dJF","title":"Surgery — Member Experiences & Open Questions","pathname":"/myhealingcommunity-docs/surgery-support-before-and-after-care/surgery-member-experiences-and-open-questions","siteSpaceId":"sitesp_Rf4YD","description":"Community-sourced surgery notes, member experiences, protocol summaries, and unresolved perioperative questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Surgery Support; Before and After Care"}]},{"id":"0TJdO08AA0dYoPGvBwNQ","title":"Biopsy Support; Before and After Care","pathname":"/myhealingcommunity-docs/biopsy-support-before-and-after-care","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based guidance for cancer patients before and after biopsy procedures","breadcrumbs":[{"label":"Home","icon":"house"}]},{"id":"P3GpGbHlOxUy3GLTrQuv","title":"Biopsy — Member Experiences & Open Questions","pathname":"/myhealingcommunity-docs/biopsy-support-before-and-after-care/biopsy-member-experiences-and-open-questions","siteSpaceId":"sitesp_Rf4YD","description":"Community-sourced biopsy notes, member experiences, practical aftercare questions, and unresolved biopsy concerns","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Biopsy Support; Before and After Care"}]},{"id":"l7ZYxVnaVEtnr26Up2R4","title":"Bone Metastases","pathname":"/myhealingcommunity-docs/bone-metastases","siteSpaceId":"sitesp_Rf4YD","description":"Shared bone-metastasis hub covering actionable research summaries, standard bone-targeted therapies, integrative strategies, protocol notes, and community member experiences.","breadcrumbs":[{"label":"Home","icon":"house"}]},{"id":"DvDYj3zHjsSpGDvtowrl","title":"Dormant cancer cells in bone: what this 2025 review reveals","pathname":"/myhealingcommunity-docs/bone-metastases/dormant-cancer-cells-in-bone-what-this-2025-review-reveals","siteSpaceId":"sitesp_Rf4YD","description":"Plain-language summary of the 2025 Bakir review on bone dormancy, reactivation, and practical takeaways","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Bone Metastases"}]},{"id":"LDoobxWYoxuUDGIQxAmi","title":"Denosumab and Zoledronic Acid","pathname":"/myhealingcommunity-docs/bone-metastases/denosumab-and-zoledronic-acid","siteSpaceId":"sitesp_Rf4YD","description":"Comparison of denosumab and zoledronic acid in bone metastases, including mechanism, trade-offs, brand names, and core reference links","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Bone Metastases"}]},{"id":"pZQE10bZVn3Usftxw5B4","title":"Integrative and Off-Label Strategies","pathname":"/myhealingcommunity-docs/bone-metastases/integrative-and-off-label-strategies","siteSpaceId":"sitesp_Rf4YD","description":"Bone-metastasis support notes on natural RANKL and NF-κB inhibitors, melatonin, propranolol, alongside ER+ andrographolide notes.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Bone Metastases"}]},{"id":"OlvhmlIUxLlnGnw63Jo7","title":"FOXM1 in Bone Metastasis","pathname":"/myhealingcommunity-docs/bone-metastases/foxm1-in-bone-metastasis","siteSpaceId":"sitesp_Rf4YD","description":"Why FOXM1 matters in metastasis, bone biology, and possible targeting strategies in bone-metastasis research","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Bone Metastases"}]},{"id":"vPEHzN6LUvhrHcZHuWTD","title":"Bone Support and Protocol Notes","pathname":"/myhealingcommunity-docs/bone-metastases/bone-support-and-protocol-notes","siteSpaceId":"sitesp_Rf4YD","description":"McKinney notes, naturopathic bone-support ideas, protocol timing, and practical implementation points for bone-metastasis support","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Bone Metastases"}]},{"id":"VYmWJKf5bvGwe0LrWIoo","title":"Group Member Tips and Supporting Evidence","pathname":"/myhealingcommunity-docs/bone-metastases/group-member-tips-and-supporting-evidence","siteSpaceId":"sitesp_Rf4YD","description":"Community-shared bone-metastasis tips paired with supporting evidence, including denosumab, zoledronic acid, WSZG, and D-limonene notes","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Bone Metastases"}]},{"id":"LfmyS4zPw7AZasK2HT2u","title":"SABR for Bone Metastases 2025 Study Summary","pathname":"/myhealingcommunity-docs/bone-metastases/sabr-for-bone-metastases-2025-study-summary","siteSpaceId":"sitesp_Rf4YD","description":"Summary of the 2025 small-scale human study on SABR for bone metastases","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Bone Metastases"}]},{"id":"KTbz1O1prWchHNp3RF32","title":"Treatment Resistance Overview","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of treatment-resistance, progression-pattern, and cross-cancer treatment-escape topics","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"}]},{"id":"ooKVqnnEZ7GwYY4C9iHF","title":"Treatment Resistance","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance","siteSpaceId":"sitesp_Rf4YD","description":"Cross-cancer resistance topics, progression patterns, and treatment-escape questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"}]},{"id":"aJrCkJFlxCZCAZvyw75V","title":"Treatment Resistance Overview","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/treatment-resistance-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of treatment-resistance topics that cut across cancer types, regimens, and biomarkers","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"}]},{"id":"fzFHBc8GnP8kYxk50eKn","title":"Drug Metabolism & Supplement Interactions","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/drug-metabolism-and-supplement-interactions","siteSpaceId":"sitesp_Rf4YD","description":"Central landing page for pharmacogenomics, enzyme pathways, transporter logic, and supplement-interaction questions across oncology treatment settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"}]},{"id":"b5b21w7G6VK7GRoDMJPw","title":"Drug Metabolism & Supplement Interactions Overview","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/drug-metabolism-and-supplement-interactions/drug-metabolism-and-supplement-interactions-overview","siteSpaceId":"sitesp_Rf4YD","description":"How to organise shared CYP, transporter, inducer, inhibitor, and regimen-specific supplement interaction topics across the site","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Drug Metabolism & Supplement Interactions"}]},{"id":"Te6kSUt1PjmjE96KAIrO","title":"Dormant Cancer Cells","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"}]},{"id":"nzi8u8xaVUwWeKlHTScZ","title":"Dormant Cancer Cells","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-1","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"}]},{"id":"Z7VCefTxtJHCWb0QkHAW","title":"Dormant Cancer Cells","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2","siteSpaceId":"sitesp_Rf4YD","description":"Cross-cancer guide to dormancy, residual disease, reactivation risk, and treatment strategy questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"}]},{"id":"uqPjGBgi5pR6FA5BjT4w","title":"Overview","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/overview","siteSpaceId":"sitesp_Rf4YD","description":"Why dormant cancer cells matter, how the section is organised, and what questions it helps answer","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"19Oybdyw8kleXNbjSO0C","title":"What Dormant Cancer Cells Are","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/what-dormant-cancer-cells-are","siteSpaceId":"sitesp_Rf4YD","description":"Plain-language guide to dormant and slow-cycling cancer cells, where they hide, and why they matter","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"Oj8ojhcYoKHkeDVLbZKD","title":"Beyond Kill It All","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/beyond-kill-it-all","siteSpaceId":"sitesp_Rf4YD","description":"Why aggressive treatment is not always the smartest answer for tiny, slow-growing, or suspected dormant disease","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"BE04jQLbi0mXxZQi99Tg","title":"Inflammation, Stress and Dormancy Escape","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/inflammation-stress-and-dormancy-escape","siteSpaceId":"sitesp_Rf4YD","description":"How inflammation, surgery, infection, and stress signalling can help dormant cancer cells reactivate","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"FJwAq3tPatyUjDJTeX4G","title":"Treatment Strategies","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/treatment-strategies","siteSpaceId":"sitesp_Rf4YD","description":"Four main ways to think about residual disease: keep dormant, wake and kill, target cells while dormant, or clear therapy-induced senescent survivors","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"UoA4WXcNFJU1JNutXRXx","title":"Dormancy-Focused Agents and Adjuncts","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/dormancy-focused-agents-and-adjuncts","siteSpaceId":"sitesp_Rf4YD","description":"Examples of drugs, repurposed agents, and compounds discussed in relation to dormant or slow-cycling cancer cells","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"67irjbQW9AIXo8KDZXi8","title":"Questions for Your Oncology Team","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/questions-for-your-oncology-team","siteSpaceId":"sitesp_Rf4YD","description":"Practical questions that help bring dormancy biology into treatment discussions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"i3TrFB6RGwOWecUZVcQH","title":"Dormancy Glossary","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/dormant-cancer-cells-2/dormancy-glossary","siteSpaceId":"sitesp_Rf4YD","description":"Quick definitions for the main terms used across the dormancy pages","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Dormant Cancer Cells"}]},{"id":"ZVDyp09WfkqeumQx9V8w","title":"Autophagy — Cancer's Escape Route","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/autophagy-cancers-escape-route","siteSpaceId":"sitesp_Rf4YD","description":"Hub for autophagy-targeted cancer strategy, including dormancy, hydroxychloroquine, host protection, and emerging combination logic","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"}]},{"id":"BypKJwG07YjOUHN2c3E3","title":"The Early Window — Part One","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/autophagy-cancers-escape-route/the-early-window-part-one","siteSpaceId":"sitesp_Rf4YD","description":"Why early autophagy inhibition matters across dormant and treatment-stressed cancer states, including CDK4/6 biology, mebendazole synergy, and the senescence escape problem","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Autophagy — Cancer's Escape Route"}]},{"id":"gXSmcRd1WnKEMeKGHzmp","title":"The Multi-Target Strategy — Part Two","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/autophagy-cancers-escape-route/the-multi-target-strategy-part-two","siteSpaceId":"sitesp_Rf4YD","description":"How the autophagy strategy is designed to layer HCQ, AKBA, metabolic pressure, and host support across multiple cancer survival pathways","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Autophagy — Cancer's Escape Route"}]},{"id":"rAVoCMrc4zwkocGvu5Eh","title":"Protecting the Host — Part Three","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/autophagy-cancers-escape-route/protecting-the-host-part-three","siteSpaceId":"sitesp_Rf4YD","description":"How to think about HCQ accumulation, mitochondrial protection, monitoring, diet support, and senolytic follow-up in the autophagy strategy","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Autophagy — Cancer's Escape Route"}]},{"id":"2UGtMwc07FkBb0iFCoKb","title":"Open Clinical Trial — COAST in Advanced Prostate Cancer","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/autophagy-cancers-escape-route/open-clinical-trial-coast-in-advanced-prostate-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Evidence-based overview of the COAST autophagy trial in advanced solid tumours and relapsed prostate cancer, including eligibility, dose design, and why the study matters","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"},{"label":"Autophagy — Cancer's Escape Route"}]},{"id":"cbAHqvY15paYmpqNSghp","title":"Senescence — The Second Escape Route","pathname":"/myhealingcommunity-docs/treatment-resistance/treatment-resistance/senescence-the-second-escape-route","siteSpaceId":"sitesp_Rf4YD","description":"Hub for therapy-induced senescence, SASP biology, senolytic strategy, and safety questions in treatment-resistant cancer care","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Treatment Resistance"},{"label":"Treatment Resistance"}]},{"id":"SsP5ah042zTPAr82abbi","title":"Testing, Monitoring & Biomarkers Overview","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/testing-monitoring-and-biomarkers-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of testing, monitoring, and biomarker topics for practical oncology use","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"}]},{"id":"ZhzpJCNDOIKd31b3IbnD","title":"Testing & Diagnostics Discussion Threads A–Z","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/testing-and-diagnostics-discussion-threads-a-z","siteSpaceId":"sitesp_Rf4YD","description":"A–Z index of Healing Cancer Study Support Group discussion threads on testing and diagnostics","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"}]},{"id":"LbrB5ZLtDd4FtJ0DRxa7","title":"Heavy Metals & Cancer","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Patient-facing guide to heavy metal burden, copper biology, testing, and practical monitoring in oncology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"}]},{"id":"nGsUBu6UPC4tyj0hXV8f","title":"Why Heavy Metals Matter in Cancer","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/why-heavy-metals-matter-in-cancer","siteSpaceId":"sitesp_Rf4YD","description":"Why heavy metal burden matters in cancer, how treatment changes metal handling, and why baseline testing can be useful","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"8oWDHt9DQmY9xCi32fsP","title":"Pathogens, Heavy Metals & the Hidden Alliance","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/pathogens-heavy-metals-and-the-hidden-alliance","siteSpaceId":"sitesp_Rf4YD","description":"How fungi, bacteria, biofilms, and heavy metals can reinforce each other in cancer settings","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"0zx21At3Bk2ij5qKLf59","title":"The Copper Story","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/the-copper-story","siteSpaceId":"sitesp_Rf4YD","description":"Why copper often rises in active cancer and why serum copper plus ceruloplasmin can be clinically useful","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"byRloiloYF3EBPrlCn06","title":"Copper Metabolism Genes and SNPs","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/copper-metabolism-genes-and-snps","siteSpaceId":"sitesp_Rf4YD","description":"Key copper transport genes that can affect copper handling, platinum chemotherapy response, and cuproptosis biology","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"WEkDnu8B18TNefwXboE1","title":"Natural Support and Timing","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/natural-support-and-timing","siteSpaceId":"sitesp_Rf4YD","description":"How to think about glutathione, NAC, ALA, selenium, binders, and timing around active cancer treatment","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"YDMBIaJgec3hEslAOlyl","title":"Understanding Heavy Metal Testing","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/understanding-heavy-metal-testing","siteSpaceId":"sitesp_Rf4YD","description":"Which metal tests are most useful, what each sample type captures, and why there is no single gold standard","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"iihUv3D7085Pj6mfknZi","title":"Accessing Testing Without a Referral","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/accessing-testing-without-a-referral","siteSpaceId":"sitesp_Rf4YD","description":"No-referral heavy metal testing options in Australia, the UK, Canada, and the United States","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"EhpSirEBUUUFhLXTCOw8","title":"Where to Start","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/heavy-metals-and-cancer/where-to-start","siteSpaceId":"sitesp_Rf4YD","description":"Practical next steps for cancer patients who want to act on heavy metal and copper questions without overcomplicating the first move","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"Heavy Metals & Cancer"}]},{"id":"X3K6GZC0y1QTaOSdkJ2c","title":"TP53 in Cancer","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"}]},{"id":"d1huqgtyTO41nfGtXQ5M","title":"TP53 in Cancer Overview","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-in-cancer-overview","siteSpaceId":"sitesp_Rf4YD","description":"Hub for TP53 test interpretation, mutation classes, treatment-planning implications, and practical support questions","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"qT2aFeXcnnH2ue3CI8A7","title":"Why Test Type Matters","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/why-test-type-matters","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"bHXfUOpspnhj3IY4FTEx","title":"TP53 SNPs and Nutrigenomics","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-snps-and-nutrigenomics","siteSpaceId":"sitesp_Rf4YD","description":"Common TP53 variants, rs1042522, and the wider DNA-repair context relevant to diet and lifestyle support","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"3oKeh0ibXRTKKnbRvkxw","title":"Germline TP53","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/germline-tp53","siteSpaceId":"sitesp_Rf4YD","description":"Inherited TP53 variants, Li-Fraumeni-spectrum risk, and why this can change treatment planning before therapy starts","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"yRIQnyboHpE2TqblqUvX","title":"Somatic TP53","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53","siteSpaceId":"sitesp_Rf4YD","description":"Tumour-acquired TP53 mutations, report interpretation, and why mutation class changes treatment logic","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"xU059sOLyK3Oi8NA81DH","title":"TP53 Mutation Types Reference","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53/tp53-mutation-types-reference","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"},{"label":"Somatic TP53"}]},{"id":"qdp0tbIR5z4D0vUNXKEV","title":"Fenbendazole and TP53","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/fenbendazole-and-tp53","siteSpaceId":"sitesp_Rf4YD","description":"Why tumour p53 status can change how favourable the fenbendazole biology looks","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"AqzxQlw4E0O1FWq42UEs","title":"Mebendazole and TP53","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/mebendazole-and-tp53","siteSpaceId":"sitesp_Rf4YD","description":"Why mebendazole appears less dependent on intact p53 than fenbendazole, and how TP53 status still shapes interpretation","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"SIVSNana2SmoiZWfNRIL","title":"Andrographis and Mutant p53","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/andrographis-and-mutant-p53","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"3jOTDdNC424ijkHHlEYs","title":"Questions for Oncologists","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/questions-for-oncologists","siteSpaceId":"sitesp_Rf4YD","description":"This page gathers the most useful patient-facing questions to during the visit in which TP53 result are shared.","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"06RIJGUKhrXYpXA57I8H","title":"Food and Lifestyle Support","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/food-and-lifestyle-support","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"qqq5sDu1Il3d4Z0gy2P9","title":"NAC in p53-Mutant Cancers","pathname":"/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/nac-in-p53-mutant-cancers","siteSpaceId":"sitesp_Rf4YD","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"Testing, Monitoring & Biomarkers"},{"label":"TP53 in Cancer"}]},{"id":"ump7IYORFHDfLx3jMQZn","title":"The Felt Science of Thriving Overview","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview","siteSpaceId":"sitesp_Rf4YD","description":"Overview of The Felt Science of Thriving and its twelve life energies","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"}]},{"id":"Pe71rf3DnC5Vi7cHgJzL","title":"Presence","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/presence","siteSpaceId":"sitesp_Rf4YD","description":"The gateway life energy and the first foundation practice in The Felt Science of Thriving","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"XbHoHJbOq1leNiY5XUJ3","title":"Safety (Psychological & Emotional)","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/safety-psychological-and-emotional","siteSpaceId":"sitesp_Rf4YD","description":"Why psychological and emotional safety is the nervous system's prerequisite for growth, and how to access it through felt experience","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"gEjFjnyeTKLh4B5alppq","title":"Empathy","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/empathy","siteSpaceId":"sitesp_Rf4YD","description":"Beginning with self-empathy: the act of turning toward your own inner experience with full, non-judgmental presence","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"IT3V955NhjiJBQlwbLA9","title":"Trust","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/trust","siteSpaceId":"sitesp_Rf4YD","description":"The inner sense that life is fundamentally safe and workable, even without guarantees about outcome","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"LTiUSx3472P8ev9ft00Z","title":"Support","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/support","siteSpaceId":"sitesp_Rf4YD","description":"The knowledge that you do not have to do this alone, and the felt experience of being genuinely supported","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"A2o1rM7EVaC50nW7m97y","title":"Beauty","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/beauty","siteSpaceId":"sitesp_Rf4YD","description":"The felt experience of being stopped by something larger than yourself, and why beauty is a healing life energy","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"XDU0unHYtBYi5qK88NqR","title":"Play","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/play","siteSpaceId":"sitesp_Rf4YD","description":"Why play is a universal human need, how it feels in the body, and how to access it through memory, imagination, and practice","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"WxIqrYui7kqIQ9OO4JAS","title":"Spontaneity","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/spontaneity","siteSpaceId":"sitesp_Rf4YD","description":"Why spontaneity is a universal human need, how it feels in the body, and how to access it through memory, imagination, and practice","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"4W2WywE0JQRGc7w7nUJf","title":"Safety (Physical)","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/safety-physical","siteSpaceId":"sitesp_Rf4YD","description":"Coming-soon page for the physical safety life energy within The Felt Science of Thriving","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"aYQZfYtKrOVcwKv8oGoq","title":"Purpose","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/purpose","siteSpaceId":"sitesp_Rf4YD","description":"Coming-soon page for the purpose life energy within The Felt Science of Thriving","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"nTQFVkLEjYZD81pTCj98","title":"Movement","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/movement","siteSpaceId":"sitesp_Rf4YD","description":"Coming-soon page for the movement life energy within The Felt Science of Thriving","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]},{"id":"jVFb6xczJIfafrTrTvyZ","title":"Belonging","pathname":"/myhealingcommunity-docs/the-felt-science-of-thriving/the-felt-science-of-thriving-overview/belonging","siteSpaceId":"sitesp_Rf4YD","description":"Coming-soon page for the belonging life energy within The Felt Science of Thriving","breadcrumbs":[{"label":"Home","icon":"house"},{"label":"The Felt Science of Thriving"},{"label":"The Felt Science of Thriving Overview"}]}]}